• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13E3 filed by New Frontier Health Corporation

    10/5/21 7:25:58 AM ET
    $NFH
    Hospital/Nursing Management
    Health Care
    Get the next $NFH alert in real time by email
    SC 13E3 1 tm2128451-1_sc13e3.htm SC 13E3 tm2128451-1_sc13e3 - none - 6.4687874s
    TABLE OF CONTENTS
    ​
    ​
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ​
    SCHEDULE 13E-3
    RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e)
    OF THE SECURITIES EXCHANGE ACT OF 1934
    ​
    NEW FRONTIER HEALTH CORPORATION
    (Name of the Issuer)
    ​
    New Frontier Health Corporation
    Unicorn II Holdings Limited
    Unicorn II Parent Limited
    Unicorn II Merger Sub Limited
    New Frontier Public Holding Ltd.
    New Frontier Capital II Limited
    New Frontier Group International Limited
    NF Founder Limited
    Strategic Healthcare Holding Ltd.
    HMJ Holdings Limited
    HMJ Holdings II Limited
    HMJ Holdings III Limited
    Unicorn Holding Partners LP
    Unicorn Holding Partners II LP
    Unicorn Holding Partners III LP
    Unicorn Holding Partners IV LP
    New Frontier Investment Management Limited
    New Frontier Investment Management II Limited
    New Frontier Investment Management III Limited
    New Frontier Investment Management IV Limited
    Kam Chung Leung
    Carl Wu
    Ying Zeng
    Carnival Investments Limited
    Max Rising International Limited
    Vivo Capital Fund IX (Cayman), L.P.
    Vivo Capital Fund IX (Cayman), LLC
    Calcite Gem Investments Group Ltd
    Warburg Pincus (Callisto) Global Growth (Cayman), L.P.
    Warburg Pincus (Europa) Global Growth (Cayman), L.P.
    Warburg Pincus Global Growth-B (Cayman), L.P.
    Warburg Pincus Global Growth-E (Cayman), L.P.
    Warburg Pincus Global Growth Partners (Cayman), L.P.
    WP Global Growth Partners (Cayman), L.P.
    Warburg Pincus China-Southeast Asia II (Cayman), L.P.
    Warburg Pincus China-Southeast Asia II-E (Cayman), L.P.
    WP China-Southeast Asia II Partners (Cayman), L.P.
    Warburg Pincus China-Southeast Asia II Partners, L.P.
    WSCP VIII EMP Onshore Investments, L.P.
    WSCP VIII EMP Offshore Investments, L.P.
    West Street Capital Partners VIII, L.P.
    West Street Capital Partners VIII — Parallel, L.P.
    WSCP VIII Offshore Investments, SLP
    Goldman Sachs Asia Strategic II Pte. Ltd.
    West Street Private Markets 2021, L.P.
    Fosun Industrial Co., Limited
    Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
    Advance Data Services Limited
    Ma Huateng
    Aspex Master Fund
    AMF-7 Holdings Limited
    Aspex Management (HK) Limited
    Ho Kei Li
    Roberta Lipson
    Benjamin Lipson Plafker Trust
    Daniel Lipson Plafker Trust
    Johnathan Lipson Plafker Trust
    Ariel Benjamin Lee Trust
    Lipson 2021 GRAT
    Yi Fang Da Sirius Inv. Limited
    Zhong Yang Securities Limited
    E Fund Management (Hong Kong) Co., Limited
    Gaorong Partners Fund V, L.P.

    TABLE OF CONTENTS
    Gaorong Partners Fund V-A, L.P.
    Gaorong Partners V Ltd.
    Smart Scene Investment Limited
    Rosy Step Holdings Limited
    Hysan Development Company Limited
    LY Holding Co., Limited
    NF SPAC Holding Limited
    Sun Hing Associates Limited
    Nan Fung Group Holdings Limited
    Pioneer Link Investments Limited
    Nan Fung Life Sciences Holdings Limited
    NF Investment Holdings Limited
    NewQuest Asia Fund IV (Singapore) Pte. Ltd.
    Pleiad Asia Master Fund
    Pleiad Asia Equity Master Fund
    Pleiad Investment Advisors Limited
    PSSF Unicorn II Ltd
    PSSF Unicorn I Ltd
    Proprium Real Estate Special Situations Fund, LP
    Proprium Real Estate Special Situations Fund GP, LP
    Proprium Real Estate Special Situations Fund GP, Ltd
    Proprium Capital Partners, L.P.
    Brave Peak Limited
    Cherish Navigation Limited
    Shimao Group Holdings Limited
    Smart Will Investments Limited
    York Asian Opportunities Investments Master Fund, L.P.
    York Capital Management Global Advisors, LLC
    James Gerard Dinan
    Yunqi China Special Investment A
    Yunqi Capital Limited
    HS Group Master Fund II Ltd.
    Yunqi Capital Cayman Limited
    HS Group (Hong Kong) Limited
    Star Advantage Global Limited
    Han Min
    Golden Majestic Investments Limited
    Luo Xiaohong
    Apex Strategic Ventures Limited
    Shi Yufeng
    Junson Development International Limited
    Silverland Assets Limited
    The Cai Family Trust
    Kui Cai
    (Names of Persons Filing Statement)
    Ordinary Shares, par value US$0.0001 per share
    (Title of Class of Securities)
    G6461G106
    (CUSIP Number)
    ​
    New Frontier Health Corporation
    10 Jiuxianqiao Road,
    Hengtong Business Park
    B7 Building, 1/F
    Chaoyang District, 100015, Beijing, China
    Tel: +86 10 5927 7000
    ​ ​
    Unicorn II Holdings Limited
    Unicorn II Parent Limited
    Unicorn II Merger Sub Limited
    New Frontier Public Holding Ltd.
    New Frontier Capital II Limited
    New Frontier Group International Limited
    NF Founder Limited
    Strategic Healthcare Holding Ltd.
    HMJ Holdings Limited
    HMJ Holdings II Limited
    HMJ Holdings III Limited
    Unicorn Holding Partners LP
    Unicorn Holding Partners II LP
    Unicorn Holding Partners III LP
    Unicorn Holding Partners IV LP
    New Frontier Investment Management Limited
    New Frontier Investment Management II Limited
    New Frontier Investment Management III Limited
    New Frontier Investment Management IV Limited
    Kam Chung Leung
    Carl Wu
    Ying Zeng
    Carnival Investments Limited
    Max Rising International Limited
    Unit 3004, Garden Square,
    No. 968, Beijing West Road,
    Jing’An, Shanghai, China
    Tel: +852 3703 3251
    ​

    TABLE OF CONTENTS
    ​
    Vivo Capital Fund IX (Cayman), L.P.
    Vivo Capital Fund IX (Cayman), LLC
    c/o : Vivo Capital LLC
    192 Lytton Ave., Palo Alto, CA 94301
    Tel: +1 650 688 0818
    ​ ​
    Calcite Gem Investments Group Ltd
    Warburg Pincus (Callisto) Global
    Growth (Cayman), L.P.
    Warburg Pincus (Europa) Global
    Growth (Cayman), L.P.
    Warburg Pincus Global Growth-B
    (Cayman), L.P.
    Warburg Pincus Global Growth-E
    (Cayman), L.P.
    Warburg Pincus Global Growth
    Partners (Cayman), L.P.
    WP Global Growth Partners
    (Cayman), L.P.
    Warburg Pincus China-Southeast
    Asia II (Cayman), L.P.
    Warburg Pincus China-Southeast
    Asia II-E (Cayman), L.P.
    WP China-Southeast Asia II
    Partners (Cayman), L.P.
    Warburg Pincus China-Southeast
    Asia II Partners, L.P.
    c/o Warburg Pincus LLC,
    450 Lexington Ave, New York,
    NY 10017
    c/o Warburg Pincus Asia LLC,
    Suite 6703, Two International
    Finance Center, Central, Hong Kong
    People’s Republic of China
    Tel: +1 212 878 0600
    ​ ​
    WSCP VIII EMP Onshore Investments, L.P.
    WSCP VIII EMP Offshore Investments, L.P.
    West Street Capital Partners VIII, L.P.
    West Street Capital Partners VIII — Parallel, L.P.
    WSCP VIII Offshore Investments, SLP
    Goldman Sachs Asia Strategic II Pte. Ltd.
    West Street Private Markets 2021, L.P.
    200 West Street New York, NY 10282-2198
    Tel: +1 212 902 1000
    ​
    ​
    Fosun Industrial Co., Limited
    Level 54, Hopewell Centre
    183 Queen’s Road East, Hong Kong Tel: +852 2980 1888
    Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
    No. 1289 Yishan Road
    Building A, Fosun Technology Park Shanghai 200233
    People’s Republic of China
    Tel: +86 21 3398 7870
    ​ ​
    Advance Data Services Limited
    Ma Huateng
    29/F, Three Pacific Place, 1 Queen’s
    Road East, Wanchai, Hong Kong
    Tel: +852 2179 5122
    ​ ​
    Aspex Master Fund
    AMF-7 Holdings Limited
    Aspex Management (HK) Limited
    Ho Kei Li
    16th Floor, St. George’s Building, 2 Ice House Street, Hong Kong
    Tel: +852 3468 4160
    ​
    ​
    Roberta Lipson
    Benjamin Lipson Plafker Trust
    Daniel Lipson Plafker Trust
    Johnathan Lipson Plafker Trust
    Ariel Benjamin Lee Trust
    Lipson 2021 GRAT
    c/o United Family Healthcare, Hengtong Office Park Building 7, Jiuxianqiao Road #10, Beijing, China
    Tel: +86 10 5927 7000
    ​ ​
    Yi Fang Da Sirius Inv. Limited
    c/o Vistra Corporate Services Centre
    Wickhams Cay II, Road Town
    Tortala
    VG1110, British Virgin Islands
    Tel: +852 3929 0911
    Zhong Yang Securities Limited
    Room 1101, 118 Connaught Road
    West, Hong Kong
    Tel: +852 3107 0731
    E Fund Management (Hong Kong)
    Co., Limited
    12/F, Nexxus Building
    41 Connaught Road Central
    Hong Kong
    Tel: +852 3929 0911
    ​ ​
    Gaorong Partners Fund V, L.P.
    Gaorong Partners Fund V-A, L.P.
    Gaorong Partners V Ltd.
    c/o Walkers Corporate Limited
    190 Elgin Avenue, George Town Grand Cayman, KY1-9008
    Cayman Islands
    Tel: +852 3974 6700
    ​

    TABLE OF CONTENTS
    ​
    Smart Scene Investment Limited
    Rosy Step Holdings Limited
    Hysan Development Company Limited
    50/F, Lee Garden One, 33 Hysan Avenue, Hong Kong
    Tel: +852 2895 5777
    ​ ​
    LY Holding Co., Limited
    Room 3008, 968 Beijing West Road,
    Shanghai
    Tel: +86 21 5185 3888
    ​ ​
    NF SPAC Holding Limited
    Sun Hing Associates Limited
    Nan Fung Group Holdings Limited
    Pioneer Link Investments Limited
    Nan Fung Life Sciences Holdings Limited
    NF Investment Holdings Limited
    23rd Floor, Nan Fung Tower, 88 Connaught Road C & 173 Des Voeux Road C, Central, Hong Kong
    Tel: +852 31083745
    ​
    ​
    NewQuest Asia Fund IV (Singapore) Pte. Ltd.
    168 Robinson Road, #20-01
    Capital Tower, Singapore 068912
    Tel: +852 3905 3600
    ​ ​
    Pleiad Asia Master Fund
    Pleiad Asia Equity Master Fund
    Pleiad Investment Advisors Limited
    26/F, 8 Wyndham Street
    Central, Hong Kong
    Tel: +852 3589 6470
    ​ ​
    PSSF Unicorn II Ltd
    PSSF Unicorn I Ltd
    Proprium Real Estate Special Situations Fund, LP
    Proprium Real Estate Special Situations Fund GP, LP
    Proprium Real Estate Special Situations Fund GP, Ltd
    Proprium Capital Partners, L.P.
    c/o Proprium Capital Partners, LP
    One Landmark Square, 20th Floor
    Stamford, CT 06901
    United States of America
    Tel: +1 203 883 0355
    ​
    ​
    Brave Peak Limited
    Cherish Navigation Limited
    Shimao Group Holdings Limited
    38th Floor, Tower One, Lippo Centre, 89 Queensway, Hong Kong
    Tel: +852 2511 9968
    ​ ​
    Smart Will Investments Limited
    34/F, Shui On Centre
    6-8 Harbour Road, Hong Kong
    Tel: +852 2879 1888
    ​ ​
    York Asian Opportunities Investments Master Fund, L.P.
    York Capital Management Global Advisors, LLC
    James Gerard Dinan
    Chater House, 8 Connaught Road Suites 809-810, Hong Kong
    Tel: +852 3718 5800
    ​
    ​
    Yunqi China Special Investment A
    Yunqi Capital Limited
    Yunqi Capital Cayman Limited
    Unit 3703, 37/F, AIA Tower
    183 Electric Road, Hong Kong
    Tel: +852 3793 3457
    HS Group Master Fund II Ltd.
    c/o Maples Corporate Service Limited PO Box 309, Ugland House
    Grand Cayman, KYI-1104
    Cayman Islands
    Tel: + 852 3577 8650
    HS Group (Hong Kong) Limited
    Suite 3302, 33/F, Two Exchange Square, 8 Connaught Place, Central, Hong Kong
    Tel: +852 3577 8650
    ​ ​
    Star Advantage Global Limited
    Han Min
    Suite 1109, Two International Finance
    Centre, 8 Finance Street, Central,
    Hong Kong
    Tel: +852 3628 2388
    ​ ​
    Golden Majestic Investments Limited
    Luo Xiaohong
    Suite 1109, Two International Finance Centre, 8 Finance Street, Central, Hong Kong
    Tel: +852 3628 2388
    ​
    ​
    Apex Strategic Ventures Limited
    Shi Yufeng
    Suite 1109, Two International Finance Centre, 8 Finance
    Street, Central, Hong Kong
    Tel: +852 3628 2388
    ​ ​
    Junson Development International Limited
    Kui Cai
    Units 5211-12, 52/F, The Center, 99 Queen’s Road
    Central, Hong Kong
    Tel: +852 2851 3663
    ​
    ​ ​ ​ ​
    Silverland Assets Limited
    The Cai Family Trust
    Level 13, 1 Queen’s Road Central, Hong Kong
    Tel: +852 2533 6333
    ​
     
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    TABLE OF CONTENTS
    ​
    With copies to:
    ​
    Howard Zhang, Esq.
    Davis Polk & Wardwell LLP
    2201, China World Office 2
    No. 1, Jian Guo Men Wai Avenue
    Beijing 100004, China
    Tel: +86 10 8567 5000
    ​ ​
    Yang Wang
    Simpson Thacher & Bartlett LLP
    3901 China World Tower
    No. 1, Jian Guo Men Wai Avenue
    Beijing 100004, China
    Tel: +86 10 5965 2976
    ​
    ​
    Weiheng Chen, Esq.
    Jie Zhu, Esq.
    Wilson Sonsini Goodrich & Rosati
    Suite 1509, 15/F Jardine House
    1 Connaught Place Central
    Hong Kong, China
    Tel: +852 3972 4955
    ​ ​
    Damian Jacobs
    Kirkland & Ellis
    26th Floor, Gloucester Tower
    The Landmark
    15 Queen’s Road Central, Hong Kong
    Tel: +852 3761 3300
    ​
    ​
    This statement is filed in connection with (check the appropriate box):
    ☐
    The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14-C or Rule 13e-3(c) under the Securities Exchange Act of 1934.
    ​
    ☐
    The filing of a registration statement under the Securities Act of 1933.
    ​
    ☐
    A tender offer
    ​
    ☒
    None of the above
    ​
    Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: ☐
    Check the following box if the filing is a final amendment reporting the results of the transaction: ☐
    Calculation of Filing Fee
    ​ ​
    Transaction Valuation*
    ​ ​ ​
    Amount of Filing Fee**
    ​
    US$703,591,284
    ​ ​ ​
    US$76,761.81
    ​
    ​
    *
    Calculated solely for the purpose of determining the filing fee in accordance with Rule 0-11(b)(1) under the Securities Exchange Act of 1934, as amended. The Transaction Valuation is calculated based on the sum of (a) the aggregate cash payment for the proposed per share cash payment of US$12.00 for the 53,781,357 issued and outstanding Ordinary Shares subject to the proposed merger of Unicorn II Merger Sub Limited with and into the issuer, plus (b) the product of 19,405,000 warrants multiplied by US$3.00 per warrant (which is the sum of the proposed per warrant cash payment of US$2.70 and per warrant consent fee of US$0.30).
    ​
    **
    The amount of the filing fee, calculated in accordance with Exchange Act Rule 0-11(b)(1) and the Securities and Exchange Commission Fee Rate Advisory #1 for Fiscal Year 2021, was calculated by multiplying the Transaction Valuation by 0.0001091.
    ​
    ☐
    Check box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting of the fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    ​
    ​ Amount Previously Paid: N/A ​ ​ Filing Party: N/A ​
    ​ Form or Registration No.: N/A ​ ​ Date Filed: N/A ​
    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of this transaction, passed upon the merits or fairness of this transaction, or passed upon the adequacy or accuracy of the disclosure in this transaction statement on schedule 13e-3. Any representation to the contrary is a criminal offense.
    ​
    ​

    TABLE OF CONTENTS​
     
    TABLE OF CONTENTS
    ​ ​ ​
    Page
    ​
    Item 1
    Summary Term Sheet
    ​
    ​ ​ ​ ​ 8 ​ ​
    Item 2
    Subject Company Information
    ​
    ​ ​ ​ ​ 8 ​ ​
    Item 3
    Identity and Background of Filing Person
    ​
    ​ ​ ​ ​ 8 ​ ​
    Item 4
    Terms of the Transaction
    ​
    ​ ​ ​ ​ 9 ​ ​
    Item 5
    Past Contracts, Transactions, Negotiations and Agreements
    ​
    ​ ​ ​ ​ 10 ​ ​
    Item 6
    Purposes of the Transaction and Plans or Proposals
    ​
    ​ ​ ​ ​ 11 ​ ​
    Item 7
    Purposes, Alternatives, Reasons and Effects
    ​
    ​ ​ ​ ​ 12 ​ ​
    Item 8
    Fairness of the Transaction
    ​
    ​ ​ ​ ​ 13 ​ ​
    Item 9
    Reports, Opinions, Appraisals and Negotiations
    ​
    ​ ​ ​ ​ 14 ​ ​
    Item 10
    Source and Amount of Funds or Other Consideration
    ​
    ​ ​ ​ ​ 14 ​ ​
    Item 11
    Interest in Securities of the Subject Company
    ​
    ​ ​ ​ ​ 15 ​ ​
    Item 12
    The Solicitation or Recommendation
    ​
    ​ ​ ​ ​ 15 ​ ​
    Item 13
    Financial Statements
    ​
    ​ ​ ​ ​ 16 ​ ​
    Item 14
    Persons/Assets, Retained, Employed, Compensated or Used
    ​
    ​ ​ ​ ​ 16 ​ ​
    Item 15
    Additional Information
    ​
    ​ ​ ​ ​ 16 ​ ​
    Item 16
    Exhibits
    ​
    ​ ​ ​ ​ 16 ​ ​
     
    i

    TABLE OF CONTENTS​
     
    INTRODUCTION
    This Rule 13e-3 transaction statement on Schedule 13E-3, together with the exhibits and annexes hereto (this “Schedule 13E-3”), is being filed with the United States Securities and Exchange Commission (the “SEC”) pursuant to Section 13(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), jointly by the following persons (each, a “Filing Person,” and collectively, the “Filing Persons”):
    (a)   New Frontier Health Corporation, an exempted company incorporated with limited liability under the laws of the Cayman Islands (the “Company”), the issuer of the ordinary shares, par value US$0.0001 per share (each, an “Ordinary Share” and collectively, the “Ordinary Shares”), that is subject to the transaction pursuant to Rule 13e-3 under the Exchange Act;
    (b)   Unicorn II Holdings Limited, an exempted company incorporated with limited liability under the laws of the Cayman Islands (“HoldCo”);
    (c)   Unicorn II Parent Limited, an exempted company incorporated with limited liability under the laws of the Cayman Islands and a wholly-owned subsidiary of HoldCo (“Parent”);
    (d)   Unicorn II Merger Sub Limited, an exempted company incorporated with limited liability under the laws of the Cayman Islands and a wholly-owned subsidiary of Parent (“Merger Sub”);
    (e)   New Frontier Public Holding Ltd., an exempted company incorporated with limited liability under the laws of the Cayman Islands (“NFPH”);
    (f)   New Frontier Capital II Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (g)   New Frontier Group International Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (h)   NF Founder Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (i)   Strategic Healthcare Holding Ltd., a company incorporated with limited liability under the laws of the British Virgin Islands;
    (j)   HMJ Holdings Limited, an exempted company incorporated with limited liability under the laws of Cayman Islands;
    (k)   HMJ Holdings II Limited, an exempted company incorporated with limited liability under the laws of Cayman Islands;
    (l)   HMJ Holdings III Limited, an exempted company incorporated with limited liability under the laws of Cayman Islands;
    (m)   Unicorn Holding Partners LP, an exempted limited partnership formed under the laws of Cayman Islands;
    (n)   Unicorn Holding Partners II LP, an exempted limited partnership formed under the laws of Cayman Islands;
    (o)   Unicorn Holding Partners III LP, an exempted limited partnership formed under the laws of Cayman Islands;
    (p)   Unicorn Holding Partners IV LP, an exempted limited partnership formed under the laws of Cayman Islands;
    (q)   New Frontier Investment Management Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands;
    (r)   New Frontier Investment Management II Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands;
     
    1

    TABLE OF CONTENTS
     
    (s)   New Frontier Investment Management III Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands;
    (t)   New Frontier Investment Management IV Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands;
    (u)   Kam Chung Leung, the chairman of the board of directors of the Company;
    (v)   Carl Wu, the president of the Company;
    (w)   Ying Zeng, the chief operating officer of the Company;
    (x)   Carnival Investments Limited, a company affiliated with Kam Chung Leung and incorporated with limited liability under the laws of the British Virgin Islands;
    (y)   Max Rising International Limited, a company affiliated with Carl Wu and incorporated with limited liability under the laws of the British Virgin Islands;
    (z)   Vivo Capital Fund IX (Cayman), L.P., an exempted limited partnership organized under the laws of the Cayman Islands;
    (aa)   Vivo Capital Fund IX (Cayman), LLC, a limited liability company incorporated and existing under the laws of the Cayman Islands;
    (bb)   Calcite Gem Investments Group Ltd, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands;
    (cc)   Warburg Pincus (Callisto) Global Growth (Cayman), L.P., an exempted limited partnership formed under the laws of the Cayman Islands;
    (dd)   Warburg Pincus (Europa) Global Growth (Cayman), L.P., an exempted limited partnership formed under the laws of the Cayman Islands;
    (ee)   Warburg Pincus Global Growth-B (Cayman), L.P., an exempted limited partnership formed under the laws of the Cayman Islands;
    (ff)   Warburg Pincus Global Growth-E (Cayman), L.P., an exempted limited partnership formed under the laws of the Cayman Islands;
    (gg)   Warburg Pincus Global Growth Partners (Cayman), L.P., an exempted limited partnership formed under the laws of the Cayman Islands;
    (hh)   WP Global Growth Partners (Cayman), L.P., an exempted limited partnership formed under the laws of the Cayman Islands;
    (ii)   Warburg Pincus China-Southeast Asia II (Cayman), L.P., an exempted limited partnership formed under the laws of the Cayman Islands;
    (jj)   Warburg Pincus China-Southeast Asia II-E (Cayman), L.P., an exempted limited partnership formed under the laws of the Cayman Islands;
    (kk)   WP China-Southeast Asia II Partners (Cayman), L.P., an exempted limited partnership formed under the laws of the Cayman Islands;
    (ll)   Warburg Pincus China-Southeast Asia II Partners, L.P., an exempted limited partnership formed under the laws of the Cayman Islands;
    (mm)   WSCP VIII EMP Onshore Investments, L.P., a limited partnership formed under the laws of the State of Delaware;
    (nn)   WSCP VIII EMP Offshore Investments, L.P., an exempted limited partnership formed under the laws of Cayman Islands;
     
    2

    TABLE OF CONTENTS
     
    (oo)   West Street Capital Partners VIII, L.P., a limited partnership formed under the laws of the State of Delaware;
    (pp)   West Street Capital Partners VIII — Parallel, L.P., a limited partnership formed under the laws of the State of Delaware;
    (qq)   WSCP VIII Offshore Investments, SLP, a special limited partnership formed under the laws of Luxembourg;
    (rr)   Goldman Sachs Asia Strategic II Pte. Ltd., a limited liability company incorporated under the laws of Singapore;
    (ss)   West Street Private Markets 2021, L.P., a limited partnership formed under the laws of the State of Delaware;
    (tt)   Fosun Industrial Co., Limited, a company incorporated with limited liability under the laws of Hong Kong Special Administrative Region of the People’s Republic of China (“Hong Kong”);
    (uu)   Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a corporation organized under the laws of the People’s Republic of China (the “PRC”);
    (vv)   Advance Data Services Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (ww)   Ma Huateng, a citizen of the PRC;
    (xx)   Aspex Master Fund, a company incorporated with limited liability under the laws of the Cayman Islands;
    (yy)   AMF-7 Holdings Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (zz)   Aspex Management (HK) Limited, a company incorporated with limited liability under the laws of Hong Kong;
    (aaa)   Ho Kei Li, a citizen of Hong Kong;
    (bbb)   Roberta Lipson, a national of the United States, Benjamin Lipson Plafker Trust, Daniel Lipson Plafker Trust, Johnathan Lipson Plafker Trust, Ariel Benjamin Lee Trust and Lipson 2021 GRAT;
    (ccc)   Yi Fang Da Sirius Inv. Limited, a company incorporated under the laws of the British Virgin Islands;
    (ddd)   Zhong Yang Securities Limited, a company incorporated and existing under the laws of Hong Kong;
    (eee)   E Fund Management (Hong Kong) Co., Limited, a company incorporated and existing under the laws of Hong Kong;
    (fff)   Gaorong Partners Fund V, L.P., a limited partnership established under the laws of the Cayman Islands;
    (ggg)   Gaorong Partners Fund V-A, L.P., a limited partnership established under the laws of the Cayman Islands;
    (hhh)   Gaorong Partners V Ltd., an exempted company incorporated with limited liability under the laws of the Cayman Islands;
    (iii)   Smart Scene Investment Limited, a company incorporated with limited liability under the laws of Hong Kong;
    (jjj)   Rosy Step Holdings Limited, a company incorporated with limited libaility under the laws of the British Virgin Islands;
     
    3

    TABLE OF CONTENTS
     
    (kkk)   Hysan Development Company Limited, a company incorporated and existing under the laws of Hong Kong;
    (lll)   LY Holding Co., Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (mmm)   NF SPAC Holding Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (nnn)   Sun Hing Associates Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (ooo)   Nan Fung Group Holdings Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (ppp)   Pioneer Link Investments Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (qqq)   Nan Fung Life Sciences Holdings Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (rrr)   NF Investment Holdings Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (sss)   NewQuest Asia Fund IV (Singapore) Pte. Ltd., a company incorporated under the laws of Singapore;
    (ttt)   Pleiad Asia Master Fund, a company incorporated under the laws of the Cayman Islands;
    (uuu)   Pleiad Asia Equity Master Fund, a company incorporated under the laws of the Cayman Islands;
    (vvv)   Pleiad Investment Advisors Limited, a company incorporated under the laws of Hong Kong;
    (www)   PSSF Unicorn II Ltd, a company incorporated and existing under the laws of the Cayman Islands;
    (xxx)   PSSF Unicorn I Ltd, a company incorporated and existing under the laws of the Cayman Islands;
    (yyy)   Proprium Real Estate Special Situations Fund, LP, a limited partnership formed under the laws of the Cayman Islands;
    (zzz)   Proprium Real Estate Special Situations Fund GP, LP, a limited partnership formed under the laws of the Cayman Islands;
    (aaaa)   Proprium Real Estate Special Situations Fund GP, Ltd, a company incorporated and existing under the laws of the Cayman Islands;
    (bbbb)   Proprium Capital Partners, L.P., a limited partnership formed under the laws of the State of Delaware;
    (cccc)   Brave Peak Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (dddd)   Cherish Navigation Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
    (eeee)   Shimao Group Holdings Limited, a company incorporated and existing under the laws of the Cayman Islands;
    (ffff)   Smart Will Investments Limited, a company incorporated with limited liability under the laws of the British Virgin Islands;
     
    4

    TABLE OF CONTENTS
     
    (gggg)   York Asian Opportunities Investments Master Fund, L.P., a hedge fund incorporated with limited liability under the laws of the Cayman Islands;
    (hhhh)   York Capital Management Global Advisors, LLC, a fund incorporated in the Cayman Islands;
    (iiii)   James Gerard Dinan, a United States citizen;
    (jjjj)   Yunqi China Special Investment A, a company incorporated with limited liability under the laws of the Cayman Islands;
    (kkkk)   Yunqi Capital Limited, a company incorporated in Hong Kong;
    (llll)   HS Group Master Fund II Ltd., a company incorporated with limited liability under the laws of the Cayman Islands;
    (mmmm)   Yunqi Capital Cayman Limited, a company incorporated with limited liability under the laws of the Cayman Islands;
    (nnnn)   HS Group (Hong Kong) Limited, a company incorporated in Hong Kong;
    (oooo)   Star Advantage Global Limited, a company incorporated and existing under the laws of the British Virgin Islands;
    (pppp)   Han Min, a citizen of Hong Kong;
    (qqqq)   Apex Strategic Ventures Limited, a company incorporated and existing under the laws of the British Virgin Islands;
    (rrrr)   Shi Yufeng, a citizen of Hong Kong;
    (ssss)   Golden Majestic Investments Limited, a company incorporated and exisitng under the laws of the British Virgin Islands;
    (tttt)   Luo Xiaohong, a citizen of the PRC;
    (uuuu)   Junson Development International Limited, a company incorporated and existing under the laws of the British Virgin Islands;
    (vvvv)   Silverland Assets Limited, a limited company incorporated and existing under the laws of the British Virgin Islands;
    (wwww)   The Cai Family Trust, a trust established under and governing by the laws of the Cayman Islands; and
    (xxxx)   Kui Cai, a citizen of Hong Kong.
    Filing Persons (b) through (xxxx) are collectively referred to herein as the “Buyer Group.” Filing Persons (e), (i), (w) through (z), (tt), (vv), (xx), (bbb), (iii), (lll) through (ooo), (cccc), (ffff), (gggg), (jjjj), (oooo), (qqqq), (ssss) and (uuuu) are collectively referred to herein as the “Supporting Securityholders.”
    On August 4, 2021, HoldCo, Parent, Merger Sub and the Company entered into an agreement and plan of merger (the “Merger Agreement”) providing for the merger of Merger Sub with and into the Company (the “Merger”) in accordance with Part XVI of the Companies Act (As Revised) of the Cayman Islands (the “Cayman Islands Companies Act”), with the Company continuing as the surviving company and a wholly-owned subsidiary of Parent.
    Under the terms of the Merger Agreement, if the Merger is completed, at the effective time of the Merger (the “Effective Time”), each Ordinary Share issued and outstanding immediately prior to the Effective Time will be cancelled in exchange for the right to receive US$12.00 per share in cash without interest, except for (a) Ordinary Shares held by HoldCo, Parent, Merger Sub, the Company (as treasury shares) or any of their direct or indirect subsidiaries, which will be cancelled and cease to exist without payment of any consideration or distribution therefor, (b) certain Ordinary Shares held by the Rollover
     
    5

    TABLE OF CONTENTS
     
    Securityholders (as defined below), which will be cancelled and cease to exist in exchange for the right of each such holder or its designated entities to receive a corresponding amount of equity securities of HoldCo, and (c) Ordinary Shares owned by holders who have validly exercised and not effectively withdrawn or lost their rights to dissent from the Merger pursuant to Section 238 of the Cayman Islands Companies Act (the “Dissenting Shares”), which will be cancelled and cease to exist and each holder thereof will be entitled to receive only the payment of fair value of such Dissenting Shares determined in accordance with Section 238 of the Cayman Islands Companies Act.
    Under the terms of the Merger Agreement and pursuant to the warrant agreement dated as of June 27, 2018 between the Company and Continental Stock Transfer & Trust Company (the “Warrant Agreement”), as amended by the Warrant Amendment (as defined below), at the Effective Time, each of the Public Warrants, Private Placement Warrants and Forward Purchase Warrants (each as defined in the Warrant Agreement and collectively, the “Warrants”) that is issued and outstanding immediately prior to the Effective Time (other than the Warrants held by NFPH) will be cancelled and cease to exist and each holder thereof will be entitled to receive US$2.70 per Warrant in cash without interest. In addition, in respect of each Warrant (other than the Warrants held by NFPH) for which the holder thereof has timely provided consent to the Warrant Amendment and has not revoked such consent prior to the deadline established by the Company for the warrantholders to submit consents, the holder of such Warrant will have the right to receive, for each such Warrant, a consent fee of US$0.30 in cash without interest.
    In addition, at the Effective Time, (a) each option to purchase Ordinary Shares (each, a “Company Option”) granted by the Company pursuant to the Company’s 2019 Omnibus Incentive Plan (the “Company Equity Plan”), whether vested or unvested, that is outstanding prior to the Effective Time will be cancelled in exchange for the right to receive, as soon as practicable after the Effective Time and in accordance with an equity incentive plan to be established by HoldCo (the “HoldCo Share Plan”), an option to purchase the same number of shares of HoldCo as the total number of the Ordinary Shares subject to such Company Option immediately prior to the Effective Time, at a per share exercise price equal to the applicable exercise price underlying the Company Option immediately prior to the Effective Time, subject to and in accordance with the terms of the Company Equity Plan and the relevant Company Option agreement in effect immediately prior to the Effective Time (with continuation of the applicable vesting terms); and (b) each restricted share unit granted under the Company Equity Plan (each, a “Company RSU Award”), whether vested or unvested, that is outstanding prior to the Effective Time will be cancelled in exchange for the right to receive, as soon as practicable after the Effective Time and in accordance with the HoldCo Share Plan, one restricted stock unit to acquire the same number of shares of HoldCo as the total number of Ordinary Shares subject to such Company RSU Award immediately prior to the Effective Time, subject to and in accordance with the terms of the Company Equity Plan and the relevant Company RSU Award agreement in effect immediately prior to the Effective Time (with continuation of the applicable vesting terms).
    In order for the Merger to be completed, the Merger Agreement, the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands, substantially in the form attached as Exhibit A to the Merger Agreement (the “Plan of Merger”), and the transactions contemplated by the Merger Agreement, including the Merger (the “Transactions”), must be authorized and approved by a special resolution (as defined in the Cayman Islands Companies Act) of the Company’s shareholders, which requires the affirmative vote of holders of Ordinary Shares representing at least two-thirds of the voting power of the Ordinary Shares present and voting in person or by proxy as a single class at an extraordinary general meeting of shareholders in accordance with Section 233(6) of the Cayman Islands Companies Act. Neither the Cayman Islands Companies Act nor the Merger Agreement requires the authorization and approval of the Merger Agreement, the Plan of Merger and the Transactions, including the Merger, to be authorized or approved by holders of a majority of the issued and outstanding Ordinary Shares unaffiliated with the Buyer Group.
    In addition, the obligations of HoldCo, Parent, Merger Sub and the Company to complete the Merger are subject to a number of other conditions set forth in the Merger Agreement, including the obtaining of the affirmative vote or written consent (the “Warrantholder Consent”) of the holders of (a) at least 50% of the number of the outstanding Public Warrants and Forward Purchase Warrants and (b) at least 50% of the number of the outstanding Private Placement Warrants, with respect to the amendment to the Warrant Agreement, to give effect to the treatment of the Warrants in accordance with the Merger Agreement (the “Warrant Amendment”).
     
    6

    TABLE OF CONTENTS
     
    As of the date of this Schedule 13E-3, the Supporting Securityholders collectively beneficially own (a) 74,233,531 Ordinary Shares, which represent approximately 56.30% of the total issued and outstanding Ordinary Shares, (b) 2,200,000 Public Warrants and 2,985,000 Forward Purchase Warrants, which collectively represent approximately 27.11% of the total number of Public Warrants and Forward Purchase Warrants outstanding, and (c) all of the outstanding 7,750,000 Private Placement Warrants, in each case, disregarding the Ordinary Shares or Warrants that the Supporting Securityholders may hold a power to vote but do not hold dispositive power. In addition, NFPH holds a power to vote granted by certain shareholders of the Company (not including any shareholder who is already a Supporting Securityholder) in respect of 10,237,559 Ordinary Shares, representing approximately 7.76% of the total issued and outstanding Ordinary Shares. Pursuant to the terms of the support agreement (the “Support Agreement”) dated as of August 4, 2021, by and among HoldCo and the Supporting Securityholders, each Supporting Securityholder agreed, among other things, (a) to vote in favor of the approval, adoption and authorization of the Merger Agreement and the approval of the Merger and any other transactions contemplated by the Merger Agreement, (b) to vote in favor of the approval of the Warrant Amendment, and (c) the Rollover Shares (as defined in the Support Agreement) and the Rollover Warrants (as defined in the Support Agreement) will be cancelled at the closing of the Merger in consideration for HoldCo shares to be subscribed for by such Supporting Securityholder or their affiliates. Furthermore, pursuant to the terms of the management rollover agreement (the “Management Rollover Agreement”) dated as of October 5, 2021, 43 shareholders of the Company who are current or former employees of the Company and who, to the best knowledge of the Company, collectively hold 953,102 Ordinary Shares (representing approximately 0.72% of the total issued and outstanding Ordinary Shares) (the “Management Rollover Securityholders”) agreed, among other things, that their Rollover Shares (as defined in the Management Rollover Agreement) will be cancelled at the closing of the Merger in consideration for HoldCo shares to be subscribed for by a designated entity. Pursuant to the terms of the rollover agreement (the “Rollover Agreement”) dated as of October 5, 2021, 13 shareholders of the Company who, to the best knowledge of the Company, collectively hold 5,363,900 Ordinary Shares (representing approximately 4.07% of the total issued and outstanding Ordinary Shares) (the “Other Rollover Securityholders”, together with Supporting Securityholders and Management Rollover Securityholders, the “Rollover Securityholders”) agreed, among other things, that their Rollover Shares (as defined in the Rollover Agreement) will be cancelled at the closing of the Merger in consideration for HoldCo shares to be subscribed for by a designated entity.
    The Company will make available to its shareholders and warrantholders a proxy and consent solicitation statement (the “proxy statement,” a preliminary copy of which is attached as Exhibit (a)-(1) to this Schedule 13E-3), relating to (a) the extraordinary general meeting of shareholders of the Company, at which the shareholders of the Company will consider and vote upon, among other proposals, a proposal to authorize and approve the Merger Agreement, the Plan of Merger and the Transactions, including the Merger, and (b) the Warrant Amendment and the solicitation of the Warrantholder Consent. A copy of the Merger Agreement, a copy of the Plan of Merger, and a copy of the substantive text of the Warrant Amendment are attached to the proxy statement as Annex A, Annex B and Annex C respectively, and are incorporated herein by reference. As of the date hereof, the proxy statement is in preliminary form and is subject to completion.
    The cross-references below are being supplied pursuant to General Instruction G to Schedule 13E-3 and show the location in the proxy statement of the information required to be included in response to the items of Schedule 13E-3. Pursuant to General Instruction F to Schedule 13E-3, the information contained in the proxy statement, including all annexes thereto, is incorporated in its entirety herein by this reference, and the responses to each item in this Schedule 13E-3 are qualified in their entirety by the information contained in the proxy statement and the annexes thereto. Capitalized terms used but not defined in this Schedule 13E-3 shall have the meanings given to them in the proxy statement.
    All information contained in this Schedule 13E-3 concerning each Filing Person has been supplied by such Filing Person, and no Filing Person has provided any disclosure with respect to any other Filing Person.
     
    7

    TABLE OF CONTENTS​​​
     
    Item 1   Summary Term Sheet
    The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    •
    “Summary Term Sheet”
    ​
    •
    “Questions and Answers about the Extraordinary General Meeting and the Merger”
    ​
    •
    “Questions and Answers about the Warrant Amendment”
    ​
    Item 2   Subject Company Information
    (a)
    Name and Address. The information set forth in the proxy statement under the following caption is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — The Parties Involved in the Merger”
    ​
    (b)
    Securities. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “The Extraordinary General Meeting — Shareholder Record Date; Shares Entitled to Vote”
    ​
    •
    “Security Ownership of Certain Beneficial Owners and Management of the Company”
    ​
    (c)
    Trading Market and Price. The information set forth in the proxy statement under the following caption is incorporated herein by reference:
    ​
    •
    “Market Price of the Ordinary Shares, Dividends and Other Matters — Market Price of the Ordinary Shares”
    ​
    (d)
    Dividends. The information set forth in the proxy statement under the following caption is incorporated herein by reference:
    ​
    •
    “Market Price of the Ordinary Shares, Dividends and Other Matters — Dividend Policy”
    ​
    (e)
    Prior Public Offerings. The information set forth in the proxy statement under the following caption is incorporated herein by reference:
    ​
    •
    “Transactions in the Ordinary Shares — Prior Public Offerings”
    ​
    (f)
    Prior Stock Purchases. The information set forth in the proxy statement under the following caption is incorporated herein by reference:
    ​
    •
    “Transactions in the Ordinary Shares”
    ​
    •
    “Special Factors — Related Party Transactions”
    ​
    Item 3   Identity and Background of Filing Person
    (a)
    Name and Address. New Frontier Health Corporation is the subject company. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — The Parties Involved in the Merger”
    ​
    •
    “Annex F — Directors and Executive Officers of Each Filing Person”
    ​
    (b)
    Business and Background of Entities. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — The Parties Involved in the Merger”
    ​
    •
    “Annex F — Directors and Executive Officers of Each Filing Person”
    ​
    (c)
    Business and Background of Natural Persons. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
     
    8

    TABLE OF CONTENTS​
     
    •
    “Summary Term Sheet — The Parties Involved in the Merger”
    ​
    •
    “Annex F — Directors and Executive Officers of Each Filing Person”
    ​
    Item 4   Terms of the Transaction
    (a)(1)
    Material Terms — Tender Offers. Not applicable.
    ​
    (a)(2)
    Material Terms — Mergers or Similar Transactions. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet”
    ​
    •
    “Questions and Answers about the Extraordinary General Meeting and the Merger”
    ​
    •
    “Questions and Answers about the Warrant Amendment”
    ​
    •
    “Special Factors”
    ​
    •
    “The Extraordinary General Meeting”
    ​
    •
    “Warrant Amendment and Warrantholder Consent”
    ​
    •
    “The Merger Agreement and Plan of Merger”
    ​
    •
    “Annex A — Agreement and Plan of Merger”
    ​
    •
    “Annex B — Plan of Merger”
    ​
    •
    “Annex C — Warrant Amendment”
    ​
    (c)
    Different Terms. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Interests of the Company’s Executive Officers and Directors in the Merger”
    ​
    •
    “Special Factors — Interests of Certain Persons in the Merger”
    ​
    •
    “The Extraordinary General Meeting — Proposals to be Considered at the Extraordinary General Meeting”
    ​
    •
    “Warrant Amendment and Warrantholder Consent”
    ​
    •
    “The Merger Agreement and Plan of Merger”
    ​
    •
    “Annex A — Agreement and Plan of Merger”
    ​
    •
    “Annex B — Plan of Merger”
    ​
    •
    “Annex C — Warrant Amendment”
    ​
    (d)
    Appraisal Rights. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Dissenters’ Rights of Shareholders”
    ​
    •
    “Questions and Answers about the Extraordinary General Meeting and the Merger”
    ​
    •
    “Questions and Answers about the Warrant Amendment”
    ​
    •
    “Special Factors — Dissenters’ Rights of Shareholders”
    ​
    •
    “Dissenters’ Rights”
    ​
    •
    “Annex E — Cayman Islands Companies Act Cap. 22 (Law 3 of 1961, as consolidated and revised) — Section 238”
    ​
     
    9

    TABLE OF CONTENTS​
     
    (e)
    Provisions for Unaffiliated Security Holders. The information set forth in the proxy statement under the following caption is incorporated herein by reference:
    ​
    •
    “Provisions for Unaffiliated Security Holders”
    ​
    (f)
    Eligibility of Listing or Trading. Not applicable.
    ​
    Item 5   Past Contracts, Transactions, Negotiations and Agreements
    (a)
    Transactions. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Special Factors — Interests of Certain Persons in the Merger”
    ​
    •
    “Special Factors — Related Party Transactions”
    ​
    •
    “Transactions in the Ordinary Shares”
    ​
    (b)
    Significant Corporate Events. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Special Factors — Background of the Merger”
    ​
    •
    “Special Factors — Reasons for the Merger and Recommendation of the Special Committee and the Board”
    ​
    •
    “Special Factors — Purposes of and Reasons for the Merger”
    ​
    •
    “Special Factors — Interests of Certain Persons in the Merger”
    ​
    •
    “Special Factors — Related Party Transactions”
    ​
    •
    “The Merger Agreement and Plan of Merger”
    ​
    •
    “Annex A — Agreement and Plan of Merger”
    ​
    •
    “Annex B — Plan of Merger”
    ​
    (c)
    Negotiations or Contacts. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Special Factors — Background of the Merger”
    ​
    •
    “Special Factors — Plans for the Company after the Merger”
    ​
    •
    “Special Factors — Interests of Certain Persons in the Merger”
    ​
    •
    “The Merger Agreement and Plan of Merger”
    ​
    •
    “Annex A — Agreement and Plan of Merger”
    ​
    •
    “Annex B — Plan of Merger”
    ​
    (e)
    Agreements Involving the Subject Company’s Securities. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Support Agreement”
    ​
    •
    “Summary Term Sheet — Consortium Agreement”
    ​
    •
    “Summary Term Sheet — Interim Investors Agreement”
    ​
    •
    “Summary Term Sheet — Warrant Amendment and Treatment of Warrants”
    ​
    •
    “Summary Term Sheet — Financing of the Merger”
    ​
    •
    Special Factors — Background of the Merger”
    ​
    •
    “Special Factors — Plans for the Company after the Merger”
    ​
    •
    “Special Factors — Financing of the Merger”
    ​
     
    10

    TABLE OF CONTENTS​
     
    •
    “Special Factors — Support Agreement”
    ​
    •
    “Special Factors — Consortium Agreement”
    ​
    •
    “Special Factors — Interim Investors Agreement”
    ​
    •
    “Special Factors — Interests of Certain Persons in the Merger”
    ​
    •
    “Special Factors — Related Party Transactions”
    ​
    •
    “Special Factors — Voting by the Supporting Securityholders at the Extraordinary General Meeting”
    ​
    •
    “Warrant Amendment and Warrantholder Consent”
    ​
    •
    “The Merger Agreement and Plan of Merger”
    ​
    •
    “Transactions in the Ordinary Shares”
    ​
    •
    “Annex A — Agreement and Plan of Merger”
    ​
    •
    “Annex B — Plan of Merger”
    ​
    •
    “Annex C — Warrant Amendment”
    ​
    Item 6   Purposes of the Transaction and Plans or Proposals
    (b)
    Use of Securities Acquired. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet”
    ​
    •
    “Questions and Answers about the Extraordinary General Meeting and the Merger”
    ​
    •
    “Questions and Answers about the Warrant Amendment”
    ​
    •
    “Special Factors — Purposes of and Reasons for the Merger”
    ​
    •
    “Special Factors — Effects of the Merger on the Company”
    ​
    •
    “The Merger Agreement and Plan of Merger”
    ​
    •
    “Annex A — Agreement and Plan of Merger”
    ​
    •
    “Annex B — Plan of Merger”
    ​
    •
    “Annex C — Warrant Amendment”
    ​
    (c)(1)-(8)
    Plans. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — The Merger”
    ​
    •
    “Summary Term Sheet — Purposes and Effects of the Merger”
    ​
    •
    “Summary Term Sheet — Plans for the Company after the Merger”
    ​
    •
    “Summary Term Sheet — Financing of the Merger”
    ​
    •
    “Summary Term Sheet — Interests of the Company’s Executive Officers and Directors in the Merger”
    ​
    •
    “Special Factors — Background of the Merger”
    ​
    •
    “Special Factors — Reasons for the Merger and Recommendation of the Special Committee and the Board”
    ​
    •
    “Special Factors — Purposes of and Reasons for the Merger”
    ​
    •
    “Special Factors — Effects of the Merger on the Company”
    ​
    •
    “Special Factors — Plans for the Company after the Merger”
    ​
     
    11

    TABLE OF CONTENTS​
     
    •
    “Special Factors — Financing of the Merger”
    ​
    •
    “Special Factors — Interests of Certain Persons in the Merger”
    ​
    •
    “Special Factors — Related Party Transactions”
    ​
    •
    “The Merger Agreement and Plan of Merger”
    ​
    •
    “Annex A — Agreement and Plan of Merger”
    ​
    •
    “Annex B — Plan of Merger”
    ​
    Item 7   Purposes, Alternatives, Reasons and Effects
    (a)
    Purposes. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Purposes and Effects of the Merger”
    ​
    •
    “Summary Term Sheet — Plans for the Company after the Merger”
    ​
    •
    “Special Factors — Reasons for the Merger and Recommendation of the Special Committee and the Board”
    ​
    •
    “Special Factors — Purposes of and Reasons for the Merger”
    ​
    (b)
    Alternatives. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Special Factors — Background of the Merger”
    ​
    •
    “Special Factors — Reasons for the Merger and Recommendation of the Special Committee and the Board”
    ​
    •
    “Special Factors — Position of the Buyer Group as to the Fairness of the Merger”
    ​
    •
    “Special Factors — Purposes of and Reasons for the Merger”
    ​
    •
    “Special Factors — Alternatives to the Merger”
    ​
    •
    “Special Factors — Effects on the Company if the Merger is not Completed”
    ​
    (c)
    Reasons. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Purposes and Effects of the Merger”
    ​
    •
    “Special Factors — Background of the Merger”
    ​
    •
    “Special Factors — Reasons for the Merger and Recommendation of the Special Committee and the Board”
    ​
    •
    “Special Factors — Position of the Buyer Group as to the Fairness of the Merger”
    ​
    •
    “Special Factors — Purposes of and Reasons for the Merger”
    ​
    •
    “Special Factors — Effects of the Merger on the Company”
    ​
    •
    “Special Factors — Alternatives to the Merger”
    ​
    (d)
    Effects. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Purposes and Effects of the Merger”
    ​
    •
    “Special Factors — Background of the Merger”
    ​
    •
    “Special Factors — Reasons for the Merger and Recommendation of the Special Committee and the Board”
    ​
     
    12

    TABLE OF CONTENTS​
     
    •
    “Special Factors — Effects of the Merger on the Company”
    ​
    •
    “Special Factors — Plans for the Company after the Merger”
    ​
    •
    “Special Factors — Effects on the Company if the Merger is not Completed”
    ​
    •
    “Special Factors — Effects of the Merger on the Company’s Net Book Value and Net Earnings”
    ​
    •
    “Special Factors — Interests of Certain Persons in the Merger”
    ​
    •
    “Special Factors — Material U.S. Federal Income Tax Consequences”
    ​
    •
    “Special Factors — Material PRC Income Tax Consequences”
    ​
    •
    “Special Factors — Material Cayman Islands Tax Consequences”
    ​
    •
    “The Merger Agreement and Plan of Merger”
    ​
    •
    “Annex A — Agreement and Plan of Merger”
    ​
    •
    “Annex B — Plan of Merger”
    ​
    Item 8   Fairness of the Transaction
    (a) -(b)
    Fairness; Factors Considered in Determining Fairness. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Recommendations of the Special Committee and the Board”
    ​
    •
    “Summary Term Sheet — Position of the Buyer Group as to the Fairness of the Merger”
    ​
    •
    “Summary Term Sheet — Opinion of the Special Committee’s Financial Advisor”
    ​
    •
    “Summary Term Sheet — Interests of the Company’s Executive Officers and Directors in the Merger”
    ​
    •
    “Special Factors — Background of the Merger”
    ​
    •
    “Special Factors — Reasons for the Merger and Recommendation of the Special Committee and the Board”
    ​
    •
    “Special Factors — Position of the Buyer Group as to the Fairness of the Merger”
    ​
    •
    “Special Factors — Opinion of the Special Committee’s Financial Advisor”
    ​
    •
    “Special Factors — Interests of Certain Persons in the Merger”
    ​
    •
    “Annex D — Opinion of Duff & Phelps, A Kroll Business operating as Kroll, LLC as Financial Advisor”
    ​
    (c)
    Approval of Security Holders. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Shareholder Vote Required to Authorize and Approve the Merger Agreement and Plan of Merger”
    ​
    •
    “Questions and Answers about the Extraordinary General Meeting and the Merger”
    ​
    •
    “The Extraordinary General Meeting — Vote Required”
    ​
    (d)
    Unaffiliated Representative. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Special Factors — Background of the Merger”
    ​
    •
    “Special Factors — Reasons for the Merger and Recommendation of the Special Committee and the Board”
    ​
    •
    “Special Factors — Opinion of the Special Committee’s Financial Advisor”
    ​
    •
    “Annex D — Opinion of Duff & Phelps, A Kroll Business operating as Kroll, LLC as Financial Advisor”
    ​
     
    13

    TABLE OF CONTENTS​​
     
    (e)
    Approval of Directors. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Recommendations of the Special Committee and the Board”
    ​
    •
    “Questions and Answers about the Extraordinary General Meeting and the Merger”
    ​
    •
    “Special Factors — Background of the Merger”
    ​
    •
    “Special Factors — Reasons for the Merger and Recommendation of the Special Committee and the Board”
    ​
    (f)
    Other Offers. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Special Factors — Background of the Merger”
    ​
    •
    “Special Factors — Reasons for the Merger and Recommendation of the Special Committee and the Board”
    ​
    Item 9   Reports, Opinions, Appraisals and Negotiations
    (a)
    Report, Opinion or Appraisal. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Opinion of the Special Committee’s Financial Advisor”
    ​
    •
    “Special Factors — Background of the Merger”
    ​
    •
    “Special Factors — Opinion of the Special Committee’s Financial Advisor”
    ​
    •
    “Annex D — Opinion of Duff & Phelps, A Kroll Business operating as Kroll, LLC as Financial Advisor”
    ​
    (b)
    Preparer and Summary of the Report, Opinion or Appraisal. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Special Factors — Opinion of the Special Committee’s Financial Advisor”
    ​
    •
    Annex D — Opinion of Duff & Phelps, A Kroll Business operating as Kroll, LLC as Financial Advisor”
    ​
    (c)
    Availability of Documents. The information set forth in the proxy statement under the following caption is incorporated herein by reference:
    ​
    •
    “Where You Can Find More Information”
    ​
    The reports, opinions or appraisals referenced in this Item 9 will be made available for inspection and copying at the principal executive offices of the Company during its regular business hours by any interested holder of the Shares or his, her or its representative who has been so designated in writing.
    Item 10   Source and Amount of Funds or Other Consideration
    (a)
    Source of Funds. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Financing of the Merger”
    ​
    •
    “Special Factors — Financing of the Merger”
    ​
    •
    “The Merger Agreement and Plan of Merger”
    ​
    •
    “Annex A — Agreement and Plan of Merger”
    ​
    •
    “Annex B — Plan of Merger”
    ​
    (b)
    Conditions. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
     
    14

    TABLE OF CONTENTS​​
     
    •
    “Summary Term Sheet — Financing of the Merger”
    ​
    •
    “Special Factors — Financing of the Merger”
    ​
    (c)
    Expenses. The information set forth in the proxy statement under the following caption is incorporated herein by reference:
    ​
    •
    “Special Factors — Fees and Expenses”
    ​
    (d)
    Borrowed Funds. The information set forth in the proxy statement under the following caption is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Financing of the Merger”
    ​
    •
    “Special Factors — Financing of the Merger”
    ​
    •
    “The Merger Agreement and Plan of Merger — Financing”
    ​
    Item 11   Interest in Securities of the Subject Company
    (a)
    Securities Ownership. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Interests of the Company’s Executive Officers and Directors in the Merger”
    ​
    •
    “Special Factors — Interests of Certain Persons in the Merger”
    ​
    •
    “Security Ownership of Certain Beneficial Owners and Management of the Company”
    ​
    (b)
    Securities Transactions. The information set forth in the proxy statement under the following caption is incorporated herein by reference:
    ​
    •
    “Transactions in the Ordinary Shares”
    ​
    Item 12   The Solicitation or Recommendation
    (d)
    Intent to Tender or Vote in a Going-Private Transaction. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Interests of the Company’s Executive Officers and Directors in the Merger”
    ​
    •
    “Summary Term Sheet — Support Agreement”
    ​
    •
    “Questions and Answers about the Extraordinary General Meeting and the Merger”
    ​
    •
    “Special Factors — Support Agreement”
    ​
    •
    “Special Factors — Voting by the Supporting Securityholders at the Extraordinary General Meeting”
    ​
    •
    “The Extraordinary General Meeting — Vote Required”
    ​
    •
    “Security Ownership of Certain Beneficial Owners and Management of the Company”
    ​
    (e)
    Recommendations of Others. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — Recommendations of the Special Committee and the Board”
    ​
    •
    “Summary Term Sheet — Position of the Buyer Group as to the Fairness of the Merger”
    ​
    •
    “Summary Term Sheet — Support Agreement”
    ​
    •
    “Summary Term Sheet — Interests of the Company’s Executive Officers and Directors in the Merger”
    ​
    •
    “Special Factors — Reasons for the Merger and Recommendation of the Special Committee and the Board”
    ​
     
    15

    TABLE OF CONTENTS​​​​
     
    •
    “Special Factors — Position of the Buyer Group as to the Fairness of the Merger”
    ​
    •
    “Special Factors — Support Agreement”
    ​
    •
    “The Extraordinary General Meeting — The Board’s Recommendation”
    ​
    Item 13   Financial Statements
    (a)
    Financial Information. The audited consolidated financial statements of the Company for the fiscal years ended December 31, 2020 and 2019 are incorporated herein by reference to the Company’s Form 20-F for the fiscal year ended December 31, 2020, filed on June 4, 2021 (see page F-1 and following pages).
    ​
    The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    •
    “Financial Information”
    ​
    •
    “Where You Can Find More Information”
    ​
    (b)
    Pro Forma Information. Not applicable.
    ​
    Item 14   Persons/Assets, Retained, Employed, Compensated or Used
    (a)
    Solicitations or Recommendations. The information set forth in the proxy statement under the following caption is incorporated herein by reference:
    ​
    •
    “The Extraordinary General Meeting — Solicitation of Proxies”
    ​
    (b)
    Employees and Corporate Assets. The information set forth in the proxy statement under the following captions is incorporated herein by reference:
    ​
    •
    “Summary Term Sheet — The Parties Involved in the Merger”
    ​
    •
    “Special Factors — Interests of Certain Persons in the Merger”
    ​
    •
    “Annex F — Directors and Executive Officers of Each Filing Person”
    ​
    Item 15   Additional Information
    (c)
    Other Material Information. The information contained in the proxy statement, including all annexes thereto, is incorporated herein by reference.
    ​
    Item 16   Exhibits
    (a)-(1)
    Preliminary Proxy and Consent Solicitation Statement of the Company dated            , 2021.
    ​
    (a)-(2)
    Notice of Extraordinary General Meeting of Shareholders of the Company, incorporated herein by reference to the proxy statement.
    ​
    (a)-(3)
    Notice of Consent Solicitation for Warrantholders of the Company, incorporated herein by reference to the proxy statement.
    ​
    (a)-(4)
    Form of Proxy Card, incorporated herein by reference to Annex G to the proxy statement.
    ​
    (a)-(5)
    Form of Consent, incorporated herein by reference to Annex H to the proxy statement.
    ​
    (a)-(6)
    Press Release issued by the Company, dated August 4, 2021, incorporated herein by reference to Exhibit 99.1 to the Current Report on Form 6-K furnished by the Company to the SEC on August 4, 2021.
    ​
    (b)-(1)
    Debt Commitment Letter, dated June 25, 2021, by and between Merger Sub and China Merchants Bank Shanghai Branch (招商银行股份有限公司上海分行), incorporated herein by reference to Exhibit 99.4 to the Schedule 13D filed by New Frontier Public Holding Ltd., Strategic Healthcare
    ​
     
    16

    TABLE OF CONTENTS
     
    Holding Ltd., Carnival Investments Limited, Kam Chung Leung, Roberta Lipson, Max Rising International Limited, Carl Wu, Ying Zeng, Vivo Capital IX (Cayman), LLC, NF SPAC Holding Limited, Sun Hing Associates Limited, Nan Fung Group Holdings Limited, Brave Peak Limited, Aspex Master Fund, Aspex Management (HK) Limited, Li Ho Kei, Smart Scene Investment Limited, LY Holding Co., Limited, Advance Data Services Limited, Yunqi China Special Investment A, York Asian Opportunities Investments Master Fund, L.P., Smart Will Investments Limited, Fosun Industrial Co., Limited and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on August 6, 2021.
    (b)-(2)
    Debt Commitment Letter, dated July 28, 2021, by and between Merger Sub and Shanghai Pudong Development Bank Co., Ltd. Putuo Sub-Branch (上海浦东发展银行股份有限公司普陀支行), incorporated herein by reference to Exhibit 99.5 to the Schedule 13D filed by New Frontier Public Holding Ltd., Strategic Healthcare Holding Ltd., Carnival Investments Limited, Kam Chung Leung, Roberta Lipson, Max Rising International Limited, Carl Wu, Ying Zeng, Vivo Capital IX (Cayman), LLC, NF SPAC Holding Limited, Sun Hing Associates Limited, Nan Fung Group Holdings Limited, Brave Peak Limited, Aspex Master Fund, Aspex Management (HK) Limited, Li Ho Kei, Smart Scene Investment Limited, LY Holding Co., Limited, Advance Data Services Limited, Yunqi China Special Investment A, York Asian Opportunities Investments Master Fund, L.P., Smart Will Investments Limited, Fosun Industrial Co., Limited and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on August 6, 2021.
    ​
    (b)-(3)
    Equity Commitment Letter, dated August 4, 2021, entered into by and between Aspex Master Fund and HoldCo.
    ​
    (b)-(4)
    Equity Commitment Letter, dated August 4, 2021, entered into by and between Yi Fang Da Sirius Inv. Limited and HoldCo.
    ​
    (b)-(5)
    Equity Commitment Letter, dated August 4, 2021, entered into by and between Gaorong Partners Fund V, L.P., Gaorong Partners Fund V-A, L.P. and HoldCo.
    ​
    (b)-(6)
    Equity Commitment Letter, dated August 4, 2021, entered into by and between WSCP VIII EMP Onshore Investments, L.P., WSCP VIII EMP Offshore Investments, L.P., West Street Capital
    Partners VIII, L.P., West Street Capital Partners VIII — Parallel, L.P., WSCP VIII Offshore Investments, SLP, Goldman Sachs Asia Strategic II Pte. Ltd., West Street Private Markets 2021, L.P. and HoldCo.
    ​
    (b)-(7)
    Equity Commitment Letter, dated August 4, 2021, entered into by and between NewQuest Asia Fund IV (Singapore) Pte. Ltd. and HoldCo.
    ​
    (b)-(8)
    Equity Commitment Letter, dated August 4, 2021, entered into by and between Pleiad Asia Master Fund, Pleiad Asia Equity Master Fund and HoldCo.
    ​
    (b)-(9)
    Equity Commitment Letter, dated August 4, 2021, entered into by and between Proprium Real Estate Special Situations Fund, LP and HoldCo.
    ​
    (b)-(10)
    Equity Commitment Letter, dated August 4, 2021, entered into by and between Unicorn Holding Partners LP and HoldCo.
    ​
    (b)-(11)
    Equity Commitment Letter, dated August 4, 2021, entered into by and between Warburg Pincus (Callisto) Global Growth (Cayman), L.P., Warburg Pincus (Europa) Global Growth (Cayman), L.P., Warburg Pincus Global Growth-B (Cayman), L.P., Warburg Pincus Global Growth-E (Cayman), L.P., Warburg Pincus Global Growth Partners (Cayman), L.P., WP Global Growth Partners (Cayman), L.P., Warburg Pincus China-Southeast Asia II (Cayman), L.P., Warburg Pincus China-Southeast Asia II-E (Cayman), L.P., WP China-Southeast Asia II Partners (Cayman), L.P. and Warburg Pincus China-Southeast Asia II Partners, L.P. (collectively, “Warburg Entities”) and HoldCo.
    ​
    (b)-(12)
    Equity Commitment Letter, dated August 4, 2021, entered into by and between Yunqi China Special Investment A and HoldCo.
    ​
     
    17

    TABLE OF CONTENTS
     
    (c)-(1)
    Opinion of Duff & Phelps, A Kroll Business Kroll, LLC, dated August 4, 2021, incorporated herein by reference to Annex D to the proxy statement.
    ​
    (c)-(2)
    Discussion Materials prepared by Duff & Phelps A Kroll Business operating as Kroll, LLC for discussion with the special committee of the board of directors of the Company, dated August 4, 2021.
    ​
    (d)-(1)
    Agreement and Plan of Merger, dated August 4, 2021, by and among the Company, HoldCo, Parent and Merger Sub, incorporated herein by reference to Annex A to the proxy statement.
    ​
    (d)-(2)
    Form of Amendment to Warrant Agreement, incorporated herein by reference to Annex C to the proxy statement.
    ​
    (d)-(3)
    Support Agreement, dated August 4, 2021, by and among HoldCo, New Frontier Public Holding Ltd., Strategic Healthcare Holding Ltd., Max Rising International Limited, Ying Zeng, Carnival Investments Limited, Vivo Capital Fund IX (Cayman), L.P., NF SPAC Holding Limited, Sun Hing Associates Limited, Nan Fung Group Holdings Limited, Brave Peak Limited, Aspex Master Fund, Roberta Lipson, Benjamin Lipson Plafker Trust, Daniel Lipson Plafker Trust, Johnathan Lipson Plafker Trust, Ariel Benjamin Lee Trust and Lipson 2021 GRAT, Advance Data Services Limited, Yunqi China Special Investment A, Smart Scene Investment Limited, York Asian Opportunities Investments Master Fund, L.P., Smart Will Investments Limited, LY Holding Co., Limited, Fosun Industrial Co., Limited, Star Advantage Global Limited, Apex Strategic Ventures Limited, Golden Majestic Investments Limited and Junson Development International Limited, incorporated herein by reference to Exhibit 99.6 to the Schedule 13D filed by New Frontier Public Holding Ltd., Strategic Healthcare Holding Ltd., Carnival Investments Limited, Kam Chung Leung, Roberta Lipson, Max Rising International Limited, Carl Wu, Ying Zeng, Vivo Capital IX (Cayman), LLC, NF SPAC Holding Limited, Sun Hing Associates Limited, Nan Fung Group Holdings Limited, Brave Peak Limited, Aspex Master Fund, Aspex Management (HK) Limited, Li Ho Kei, Smart Scene Investment Limited, LY Holding Co., Limited, Advance Data Services Limited, Yunqi China Special Investment A, York Asian Opportunities Investments Master Fund, L.P., Smart Will Investments Limited, Fosun Industrial Co., Limited and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on August 6, 2021.
    ​
    (d)-(4)
    Limited Guarantee, dated August 4, 2021, issued and delivered by Unicorn Holding Partners LP to the Company.
    ​
    (d)-(5)
    Limited Guarantee, dated August 4, 2021, issued and delivered by Aspex Master Fund to the Company.
    ​
    (d)-(6)
    Limited Guarantee, dated August 4, 2021, issued and delivered by Yunqi China Special Investment A to the Company.
    ​
    (d)-(7)
    Limited Guarantee, dated August 4, 2021, issued and delivered by WSCP VIII EMP Onshore Investments, L.P., WSCP VIII EMP Offshore Investments, L.P., West Street Capital Partners VIII, L.P., West Street Capital Partners VIII — Parallel, L.P., WSCP VIII Offshore Investments, SLP, Goldman Sachs Asia Strategic II Pte. Ltd. and West Street Private Markets 2021, L.P. to the Company.
    ​
    (d)-(8)
    Limited Guarantee, dated August 4, 2021, issued and delivered by Warburg Entities to the Company.
    ​
    (d)-(9)
    Limited Guarantee, dated August 4, 2021, issued and delivered by Proprium Real Estate Special Situations Fund, LP to the Company.
    ​
    (d)-(10)
    Limited Guarantee, dated August 4, 2021, issued and delivered by Yi Fang Da Sirius Inv. Limited to the Company.
    ​
    (d)-(11)
    Limited Guarantee, dated August 4, 2021, issued and delivered by Gaorong Partners Fund V, L.P. and Gaorong Partners Fund V-A, L.P. to the Company.
    ​
    (d)-(12)
    Limited Guarantee, dated August 4, 2021, issued and delivered by Pleiad Asia Master Fund and Pleiad Asia Equity Master Fund to the Company.
    ​
     
    18

    TABLE OF CONTENTS
     
    (d)-(13)
    Limited Guarantee, dated August 4, 2021, issued and delivered by NewQuest Asia Fund IV (Singapore) Pte. Ltd. to the Company.
    ​
    (d)-(14)
    Consortium Agreement, dated February 9, 2021, by and among New Frontier Public Holding Ltd., Carnival Investments Limited, Roberta Lipson and trusts affiliated with Roberta Lipson, Max Rising International Limited, Ying Zeng, Vivo Capital Fund IX (Cayman), L.P., NF SPAC Holding Limited, Sun Hing Associates Limited, Brave Peak Limited, Aspex Master Fund, Smart Scene Investment Limited and LY Holding Co., Limited, incorporated herein by reference to Exhibit 1 to the Schedule 13D filed by New Frontier Public Holding Ltd., Carnival Investments Limited, Kam Chung Leung, Roberta Lipson, Max Rising International Limited, Carl Wu, Ying Zeng, Vivo Capital IX (Cayman), LLC, NF SPAC Holding Limited, Sun Hing Associates Limited, Nan Fung Group Holdings Limited, Brave Peak Limited, Aspex Master Fund, Aspex Management (HK) Limited, Li Ho Kei, Smart Scene Investment Limited and LY Holding Co., Limited on February 16, 2021.
    ​
    (d)-(15)
    Interim Investors Agreement, dated August 4, 2021, by and among HoldCo, Parent, Merger Sub, New Frontier Public Holding Ltd., Strategic Healthcare Holding Ltd. Carnival Investments Limited, Max Rising International Limited, Ying Zeng, HMJ Holdings Limited, Vivo Capital Fund IX (Cayman), L.P., NF SPAC Holding Limited, Sun Hing Associates Limited, Nan Fung Group Holdings Limited, Brave Peak Limited, Aspex Master Fund, AMF-7 Holdings Limited, Roberta Lipson, Benjamin Lipson Plafker Trust, Daniel Lipson Plafker Trust, Johnathan Lipson Plafker Trust, Ariel Benjamin Lee Trust and Lipson 2021 GRAT, Advance Data Services Limited, Yunqi China Special Investment A, Smart Scene Investment Limited, York Asian Opportunities Investments Master Fund, L.P., Smart Will Investments Limited, LY Holding Co., Limited, Fosun Industrial Co., Limited, WSCP VIII EMP Onshore Investments, L.P., WSCP VIII EMP Offshore Investments, L.P., West Street Capital Partners VIII, L.P., West Street Capital Partners VIII —  Parallel, L.P., WSCP VIII Offshore Investments, SLP, Goldman Sachs Asia Strategic II Pte. Ltd., West Street Private Markets 2021, L.P., Calcite Gem Investments Group Ltd, PSSF Unicorn II Ltd, Yi Fang Da Sirius Inv. Limited, Gaorong Partners Fund V, L.P. and Gaorong Partners Fund V-A, L.P., Pleiad Asia Master Fund, Pleiad Asia Equity Master Fund, NewQuest Asia Fund IV (Singapore) Pte. Ltd., HMJ Holdings II Limited, HMJ Holdings III Limited, Star Advantage Global Limited, Apex Strategic Ventures Limited, Golden Majestic Investments Limited and Junson Development International Limited, incorporated herein by reference to Exhibit 99.7 to the Schedule 13D filed by New Frontier Public Holding Ltd., Strategic Healthcare Holding Ltd., Carnival Investments Limited, Kam Chung Leung, Roberta Lipson, Max Rising International Limited, Carl Wu, Ying Zeng, Vivo Capital IX (Cayman), LLC, NF SPAC Holding Limited, Sun Hing Associates Limited, Nan Fung Group Holdings Limited, Brave Peak Limited, Aspex Master Fund, Aspex Management (HK) Limited, Li Ho Kei, Smart Scene Investment Limited, LY Holding Co., Limited, Advance Data Services Limited, Yunqi China Special Investment A, York Asian Opportunities Investments Master Fund, L.P., Smart Will Investments Limited, Fosun Industrial Co., Limited and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on August 6, 2021.
    ​
    (d)-(16)
    Management Rollover Agreement, dated October 5, 2021, by and among HoldCo, HMJ Holdings II Limited and certain other parties therein.
    ​
    (d)-(17)
    Rollover Agreement, dated October 5, 2021, by and among HoldCo, HMJ Holdings III Limited and certain other parties therein.
    ​
    (f)-(1)
    Dissenters’ Rights, incorporated herein by reference to the section entitled “Dissenters’ Rights” in the proxy statement.
    ​
    (f)-(2)
    Section 238 of the Cayman Islands Companies Act Cap. 22 (Law 3 of 1961, as consolidated and revised), incorporated herein by reference to Annex E to the proxy statement.
    ​
    (g)
    Not applicable.
    ​
     
    19

    TABLE OF CONTENTS​
     
    SIGNATURES
    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Date: October 5, 2021
    ​ ​ ​ ​ New Frontier Health Corporation ​
    ​ ​ ​ ​
    By:
    /s/ Lawrence Chia
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Lawrence Chia ​
    ​ ​ ​ ​ Title: Chairman of the Special Committee ​
    ​ ​ ​ ​ Unicorn II Holdings Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ Unicorn II Parent Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ Unicorn II Merger Sub Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ New Frontier Public Holding Ltd. ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ New Frontier Capital II Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ New Frontier Group International Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ NF Founder Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ Strategic Healthcare Holding Ltd. ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ HMJ Holdings Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ HMJ Holdings II Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ HMJ Holdings III Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ Unicorn Holding Partners LP ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ Unicorn Holding Partners II LP ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ Unicorn Holding Partners III LP ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ Unicorn Holding Partners IV LP ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ New Frontier Investment Management Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ New Frontier Investment Management II Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ New Frontier Investment Management III Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ New Frontier Investment Management IV Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ Kam Chung Leung ​
    ​ ​ ​ ​
    /s/ Kam Chung Leung
    ​
    ​
    ​ ​ ​ ​ Carl Wu ​
    ​ ​ ​ ​
    /s/ Carl Wu
    ​
    ​
    ​ ​ ​ ​ Ying Zeng ​
    ​ ​ ​ ​
    /s/ Ying Zeng
    ​
    ​
    ​ ​ ​ ​ Carnival Investments Limited ​
    ​ ​ ​ ​
    By:
    /s/ Kam Chung Leung
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Kam Chung Leung ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Max Rising International Limited ​
    ​ ​ ​ ​
    By:
    /s/ Carl Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carl Wu ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ Vivo Capital Fund IX (Cayman), L.P. ​
    ​ ​ ​ ​
    By:
    /s/ Frank Kung
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Frank Kung ​
    ​ ​ ​ ​ Title: Managing Member of Vivo Capital IX (Cayman), LLC, General Partner ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ Vivo Capital Fund IX (Cayman), LLC ​
    ​ ​ ​ ​
    By:
    /s/ Frank Kung
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Frank Kung ​
    ​ ​ ​ ​ Title: Managing Member of Vivo Capital IX (Cayman), LLC, General Partner ​
    ​ ​ ​ ​ Calcite Gem Investments Group Ltd ​
    ​ ​ ​ ​
    By:
    /s/ Steven G. Glenn
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Steven G. Glenn ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ WARBURG PINCUS (CALLISTO) GLOBAL GROWTH (CAYMAN), L.P. ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) Global Growth
    GP, L.P., its general partner
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) Global Growth
    GP LLC, its general partner
    ​
    ​ ​ ​ ​ By: Warburg Pincus Partners II (Cayman), L.P.,
    its managing member
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Bermuda) Private Equity
    GP Ltd., its general partner
    ​
    ​ ​ ​ ​
    By:
    /s/ Steven G. Glenn
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Steven G. Glenn ​
    ​ ​ ​ ​ Title: Authorised Signatory ​
    ​ ​ ​ ​ WARBURG PINCUS (EUROPA) GLOBAL GROWTH (CAYMAN), L.P. ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) Global Growth
    GP, L.P., its general partner
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) Global Growth
    GP LLC, its general partner
    ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ By: Warburg Pincus Partners II (Cayman), L.P.,
    its managing member
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Bermuda) Private Equity
    GP Ltd., its general partner
    ​
    ​ ​ ​ ​
    By:
    /s/ Steven G. Glenn
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Steven G. Glenn ​
    ​ ​ ​ ​ Title: Authorised Signatory ​
    ​ ​ ​ ​ WARBURG PINCUS GLOBAL GROWTH-B (CAYMAN), L.P. ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) Global Growth
    GP, L.P., its general partner
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) Global Growth
    GP LLC, its general partner
    ​
    ​ ​ ​ ​ By: Warburg Pincus Partners II (Cayman), L.P.,
    its managing member
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Bermuda) Private Equity
    GP Ltd., its general partner
    ​
    ​ ​ ​ ​
    By:
    /s/ Steven G. Glenn
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Steven G. Glenn ​
    ​ ​ ​ ​ Title: Authorised Signatory ​
    ​ ​ ​ ​ WARBURG PINCUS GLOBAL GROWTH-E (CAYMAN), L.P. ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) Global Growth
    GP, L.P., its general partner
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) Global Growth
    GP LLC, its general partner
    ​
    ​ ​ ​ ​ By: Warburg Pincus Partners II (Cayman), L.P.,
    its managing member
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Bermuda) Private Equity
    GP Ltd., its general partner
    ​
    ​ ​ ​ ​
    By:
    /s/ Steven G. Glenn
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Steven G. Glenn ​
    ​ ​ ​ ​ Title: Authorised Signatory ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ WARBURG PINCUS GLOBAL GROWTH PARTNERS (CAYMAN), L.P. ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) Global Growth
    GP, L.P., its general partner
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) Global Growth
    GP LLC, its general partner
    ​
    ​ ​ ​ ​ By: Warburg Pincus Partners II (Cayman), L.P.,
    its managing member
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Bermuda) Private Equity GP Ltd., its general partner ​
    ​ ​ ​ ​
    By:
    /s/ Steven G. Glenn
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Steven G. Glenn ​
    ​ ​ ​ ​ Title: Aurthorised Signatory ​
    ​ ​ ​ ​ WP GLOBAL GROWTH PARTNERS (CAYMAN), L.P. ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) Global Growth
    GP, L.P., its general partner
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) Global Growth
    GP LLC, its general partner
    ​
    ​ ​ ​ ​ By: Warburg Pincus Partners II (Cayman), L.P.,
    its managing member
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Bermuda) Private Equity
    GP Ltd., its general partner
    ​
    ​ ​ ​ ​
    By:
    /s/ Steven G. Glenn
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Steven G. Glenn ​
    ​ ​ ​ ​ Title: Aurthorised Signatory ​
    ​ ​ ​ ​ WARBURG PINCUS CHINA-SOUTHEAST ASIA II (CAYMAN), L.P. ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) China-Southeast Asia II GP, L.P., its general partner ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) China-Southeast Asia II GP LLC, its general partner ​
    ​ ​ ​ ​ By: Warburg Pincus Partners II (Cayman), L.P., its managing member ​
    ​ ​ ​ ​ By: Warburg Pincus (Bermuda) Private Equity GP Ltd., its general partner ​
    ​ ​ ​ ​
    By:
    /s/ Steven G. Glenn
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Steven G. Glenn ​
    ​ ​ ​ ​ Title: Authorised Signatory ​
    ​ ​ ​ ​ WARBURG PINCUS CHINA-SOUTHEAST ASIA II-E (CAYMAN), L.P. ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) China-Southeast Asia II GP, L.P., its general partner ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) China-Southeast Asia II GP LLC, its general partner ​
    ​ ​ ​ ​ By: Warburg Pincus Partners II (Cayman), L.P.,
    its managing member
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Bermuda) Private Equity
    GP Ltd., its general partner
    ​
    ​ ​ ​ ​
    By:
    /s/ Steven G. Glenn
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Steven G. Glenn ​
    ​ ​ ​ ​ Title: Authorised Signatory ​
    ​ ​ ​ ​ WP CHINA-SOUTHEAST ASIA II PARTNERS (CAYMAN), L.P. ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) China-Southeast Asia II GP, L.P., its general partner ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) China-Southeast Asia II GP LLC, its general partner ​
    ​ ​ ​ ​ By: Warburg Pincus Partners II (Cayman), L.P., its managing member ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ By: Warburg Pincus (Bermuda) Private Equity GP Ltd., its general partner ​
    ​ ​ ​ ​
    By:
    /s/ Steven G. Glenn
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Steven G. Glenn ​
    ​ ​ ​ ​ Title: Authorised Signatory ​
    ​ ​ ​ ​ WARBURG PINCUS CHINA-SOUTHEAST ASIA II PARTNERS, L.P. ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) China-Southeast Asia II GP, L.P., its general partner ​
    ​ ​ ​ ​ By: Warburg Pincus (Cayman) China-Southeast Asia II GP LLC, its general partner ​
    ​ ​ ​ ​ By: Warburg Pincus Partners II (Cayman), L.P.,
    its managing member
    ​
    ​ ​ ​ ​ By: Warburg Pincus (Bermuda) Private Equity
    GP Ltd., its general partner
    ​
    ​ ​ ​ ​
    By:
    /s/ Steven G. Glenn
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Steven G. Glenn ​
    ​ ​ ​ ​ Title: Authorised Signatory ​
    ​ ​ ​ ​ WSCP VIII EMP Onshore Investments, L.P. ​
    ​ ​ ​ ​ By: WSCP VIII ESC ADVISORS, L.L.C., its
    General Partner
    ​
    ​ ​ ​ ​
    By:
    /s/ Carey Ziegler
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carey Ziegler ​
    ​ ​ ​ ​ Title: Vice President ​
    ​ ​ ​ ​ WSCP VIII EMP Offshore Investments, L.P. ​
    ​ ​ ​ ​ By: WSCP VIII ESC ADVISORS, L.L.C., its
    General Partner
    ​
    ​ ​ ​ ​
    By:
    /s/ Carey Ziegler
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carey Ziegler ​
    ​ ​ ​ ​ Title: Vice President ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ West Street Capital Partners VIII, L.P. ​
    ​ ​ ​ ​ By: Goldman Sachs & Co. LLC,
    Attorney-in-Fact
    ​
    ​ ​ ​ ​
    By:
    /s/ Carey Ziegler
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carey Ziegler ​
    ​ ​ ​ ​ Title: Attorney-in-fact ​
    ​ ​ ​ ​ West Street Capital Partners VIII — Parallel, L.P. ​
    ​ ​ ​ ​ By: Goldman Sachs & Co. LLC,
    Attorney-in-Fact
    ​
    ​ ​ ​ ​
    By:
    /s/ Carey Ziegler
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carey Ziegler ​
    ​ ​ ​ ​ Title: Attorney-in-fact ​
    ​ ​ ​ ​ WSCP VIII Offshore Investments, SLP ​
    ​ ​ ​ ​ By: WEST STREET CAPITAL PARTNERS VIII ADVISORS, S.À R.L., its General Partner ​
    ​ ​ ​ ​
    By:
    /s/ Stéphane Lachance
    /s/ Paul Brogan​
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Stéphane Lachance
              Paul Brogan​
    ​
    ​ ​ ​ ​ Title: Managers ​
    ​ ​ ​ ​ Goldman Sachs Asia Strategic II Pte. Ltd. ​
    ​ ​ ​ ​
    By:
    /s/ Tan Ching Chek
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Tan Ching Chek ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ West Street Private Markets 2021, L.P. ​
    ​ ​ ​ ​ By: Goldman Sachs & Co. LLC,
    its Investment Manager
    ​
    ​ ​ ​ ​
    By:
    /s/ Carey Ziegler
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Carey Ziegler ​
    ​ ​ ​ ​ Title: Attorney-in-fact ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ Fosun Industrial Co., Limited ​
    ​ ​ ​ ​
    By:
    /s/ Xiaohui Guan
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Xiaohui Guan ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ​
    ​ ​ ​ ​
    By:
    /s/ Yifang Wu
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Yifang Wu ​
    ​ ​ ​ ​ Title: Executive Director, Chairman and Chief Executive Officer ​
    ​ ​ ​ ​ Advance Data Services Limited ​
    ​ ​ ​ ​
    By:
    /s/ Ma Huateng
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Ma Huateng ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Ma Huateng ​
    ​ ​ ​ ​
    /s/ Ma Huateng
    ​
    ​
    ​ ​ ​ ​ Aspex Master Fund ​
    ​ ​ ​ ​
    By:
    /s/ Li, Ho Kei
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Li, Ho Kei ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ AMF-7 Holdings Limited ​
    ​ ​ ​ ​
    By:
    /s/ Li, Ho Kei
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Li, Ho Kei ​
    ​ ​ ​ ​ Title: Director ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ Aspex Management (HK) Limited ​
    ​ ​ ​ ​
    By:
    /s/ Li, Ho Kei
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Li, Ho Kei ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Ho Kei Li ​
    ​ ​ ​ ​
    /s/ Ho Kei Li
    ​
    ​
    ​ ​ ​ ​ Roberta Lipson ​
    ​ ​ ​ ​
    /s/ Roberta Lipson
    ​
    ​
    ​ ​ ​ ​ Benjamin Lipson Plafker Trust ​
    ​ ​ ​ ​
    By:
    /s/ Roberta Lipson
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Roberta Lipson ​
    ​ ​ ​ ​ Title: Trustee ​
    ​ ​ ​ ​ Daniel Lipson Plafker Trust ​
    ​ ​ ​ ​
    By:
    /s/ Roberta Lipson
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Roberta Lipson ​
    ​ ​ ​ ​ Title: Trustee ​
    ​ ​ ​ ​ Johnathan Lipson Plafker Trust ​
    ​ ​ ​ ​
    By:
    /s/ Roberta Lipson
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Roberta Lipson ​
    ​ ​ ​ ​ Title: Trustee ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ Ariel Benjamin Lee Trust ​
    ​ ​ ​ ​
    By:
    /s/ Roberta Lipson
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Roberta Lipson ​
    ​ ​ ​ ​ Title: Trustee ​
    ​ ​ ​ ​ Lipson 2021 GRAT ​
    ​ ​ ​ ​
    By:
    /s/ Roberta Lipson
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Roberta Lipson ​
    ​ ​ ​ ​ Title: Trustee ​
    ​ ​ ​ ​ Yi Fang Da Sirius Inv. Limited ​
    ​ ​ ​ ​
    By:
    /s/ Shi Feng
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Shi Feng ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​
    By:
    /s/ Ho Kwok Wah
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Ho Kwok Wah ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ Zhong Yang Securities Limited ​
    ​ ​ ​ ​
    By:
    /s/ Yang Junli
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Yang Junli ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ E Fund Management (Hong Kong) Co., Limited ​
    ​ ​ ​ ​
    By:
    /s/ Shi Feng
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Shi Feng ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​
    By:
    /s/ Ho Kwok Wah
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Ho Kwok Wah ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ Gaorong Partners Fund V, L.P. ​
    ​ ​ ​ ​
    By:
    /s/ Peter Wong
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Peter Wong ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ Gaorong Partners Fund V-A, L.P. ​
    ​ ​ ​ ​
    By:
    /s/ Peter Wong
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Peter Wong ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ Gaorong Partners V Ltd. ​
    ​ ​ ​ ​
    By:
    /s/ Peter Wong
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Peter Wong ​
    ​ ​ ​ ​ Title: Authorized Signatory ​
    ​ ​ ​ ​ Smart Scene Investment Limited ​
    ​ ​ ​ ​
    By:
    /s/ Lui Kon Wai
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Lui Kon Wai ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Rosy Step Holdings Limited ​
    ​ ​ ​ ​
    By:
    /s/ Lui Kon Wai
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Lui Kon Wai ​
    ​ ​ ​ ​ Title: Director ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ Hysan Development Company Limited ​
    ​ ​ ​ ​
    By:
    /s/ Hao Shu Yan
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Hao Shu Yan ​
    ​ ​ ​ ​ Title: Company Secretary ​
    ​ ​ ​ ​ LY Holding Co., Limited ​
    ​ ​ ​ ​
    By:
    /s/ Ng Ka Lam
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Ng Ka Lam ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ NF SPAC Holding Limited ​
    ​ ​ ​ ​
    By:
    /s/ Chun Wai Nelson Tang
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Chun Wai Nelson Tang ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Sun Hing Associates Limited ​
    ​ ​ ​ ​
    By:
    /s/ Chun Wai Nelson Tang
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Chun Wai Nelson Tang ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Nan Fung Group Holdings Limited ​
    ​ ​ ​ ​
    By:
    /s/ Chun Wai Nelson Tang
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Chun Wai Nelson Tang ​
    ​ ​ ​ ​ Title: Director ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ Pioneer Link Investments Limited ​
    ​ ​ ​ ​
    By:
    /s/ Chun Wai Nelson Tang
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Chun Wai Nelson Tang ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Nan Fung Life Sciences Holdings Limited ​
    ​ ​ ​ ​
    By:
    /s/ Chun Wai Nelson Tang
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Chun Wai Nelson Tang ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ NF Investment Holdings Limited ​
    ​ ​ ​ ​
    By:
    /s/ Chun Wai Nelson Tang
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Chun Wai Nelson Tang ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ NewQuest Asia Fund IV (Singapore) Pte. Ltd. ​
    ​ ​ ​ ​
    By:
    /s/ Darren Charles Massara
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Darren Charles Massara ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Pleiad Asia Master Fund ​
    ​ ​ ​ ​
    By:
    /s/ Marc Towers
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Marc Towers ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Pleiad Asia Equity Master Fund ​
    ​ ​ ​ ​
    By:
    /s/ Marc Towers
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Marc Towers ​
    ​ ​ ​ ​ Title: Director ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ Pleiad Investment Advisors Limited ​
    ​ ​ ​ ​
    By:
    /s/ Masaki Taniguchi
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Masaki Taniguchi ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ PSSF Unicorn II Ltd ​
    ​ ​ ​ ​
    By:
    /s/ Natalie Medlicott
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Natalie Medlicott ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ PSSF Unicorn I Ltd ​
    ​ ​ ​ ​
    By:
    /s/ Natalie Medlicott
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Natalie Medlicott ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Proprium Real Estate Special Situations
    Fund, LP
    ​
    ​ ​ ​ ​
    By:
    /s/ Natalie Medlicott
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Natalie Medlicott ​
    ​ ​ ​ ​ Title: Vice President of General Partner of
    General Partner
    ​
    ​ ​ ​ ​ Proprium Real Estate Special Situations Fund 
    GP, LP
    ​
    ​ ​ ​ ​
    By:
    /s/ Natalie Medlicott
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Natalie Medlicott ​
    ​ ​ ​ ​ Title: Vice President of General Partner ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ Proprium Real Estate Special Situations Fund 
    GP, Ltd
    ​
    ​ ​ ​ ​
    By:
    /s/ Natalie Medlicot
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Natalie Medlicott ​
    ​ ​ ​ ​ Title: Vice President ​
    ​ ​ ​ ​ Proprium Capital Partners, L.P. ​
    ​ ​ ​ ​
    By:
    /s/ Natalie Medlicot
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Natalie Medlicott ​
    ​ ​ ​ ​ Title: Vice President ​
    ​ ​ ​ ​ Brave Peak Limited ​
    ​ ​ ​ ​
    By:
    /s/ Hui Mei Mei, Carol
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Hui Mei Mei, Carol ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Cherish Navigation Limited ​
    ​ ​ ​ ​
    By:
    /s/ Hui Mei Mei, Carol
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Hui Mei Mei, Carol ​
    ​ ​ ​ ​ Title: Authorised Signatory ​
    ​ ​ ​ ​ Shimao Group Holdings Limited ​
    ​ ​ ​ ​
    By:
    /s/ Hui Mei Mei, Carol
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Hui Mei Mei, Carol ​
    ​ ​ ​ ​ Title: Authorised Signatory ​
    ​ ​ ​ ​ Smart Will Investments Limited ​
    ​ ​ ​ ​
    By:
    /s/ Chan Wai Kan
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Chan Wai Kan ​
    ​ ​ ​ ​ Title: Director ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ York Asian Opportunities Investments Master Fund, L.P. ​
    ​ ​ ​ ​
    By:
    /s/ James Gerard Dinan
    ​
    ​
    ​
    ​ ​ ​ ​ Name: James Gerard Dinan ​
    ​ ​ ​ ​ Title: CEO ​
    ​ ​ ​ ​ York Capital Management Global Advisors, LLC ​
    ​ ​ ​ ​
    By:
    /s/ James Gerard Dinan
    ​
    ​
    ​
    ​ ​ ​ ​ Name: James Gerard Dinan ​
    ​ ​ ​ ​ Title: CEO ​
    ​ ​ ​ ​ James Gerard Dinan ​
    ​ ​ ​ ​
    /s/ James Gerard Dinan
    ​
    ​
    ​ ​ ​ ​ Yunqi China Special Investment A ​
    ​ ​ ​ ​
    By:
    /s/ Wang Christopher Min Fang
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Wang Christopher Min Fang ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Yunqi Capital Limited ​
    ​ ​ ​ ​
    By:
    /s/ Wang Christopher Min Fang
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Wang Christopher Min Fang ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ HS Group Master Fund II Ltd. ​
    ​ ​ ​ ​
    By:
    /s/ Michael Garrow
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Michael Garrow ​
    ​ ​ ​ ​ Title: Director ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ Yunqi Capital Cayman Limited ​
    ​ ​ ​ ​
    By:
    /s/ Wang Christopher Min Fang
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Wang Christopher Min Fang ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ HS Group (Hong Kong) Limited ​
    ​ ​ ​ ​
    By:
    /s/ Johannes Kaps
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Johannes Kaps ​
    ​ ​ ​ ​ Title: Director, Chief Executive Officer ​
    ​ ​ ​ ​ Star Advantage Global Limited ​
    ​ ​ ​ ​
    By:
    /s/ Han Min
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Han Min ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Han Min ​
    ​ ​ ​ ​
    /s/ Han Min
    ​
    ​
    ​ ​ ​ ​ Golden Majestic Investments Limited ​
    ​ ​ ​ ​
    By:
    /s/ Luo Xiaohong
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Luo Xiaohong ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Luo Xiaohong ​
    ​ ​ ​ ​
    /s/ Luo Xiaohong
    ​
    ​
     

    TABLE OF CONTENTS
     
    ​ ​ ​ ​ Apex Strategic Ventures Limited ​
    ​ ​ ​ ​
    By:
    /s/ Jin Yuanying
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Jin Yuanying ​
    ​ ​ ​ ​ Title: Authorised Signer ​
    ​ ​ ​ ​ Shi Yufeng ​
    ​ ​ ​ ​
    /s/ Shi Yufeng
    ​
    ​
    ​ ​ ​ ​ Junson Development International Limited ​
    ​ ​ ​ ​
    By:
    /s/ Kui Cai
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Kui Cai ​
    ​ ​ ​ ​ Title: Director ​
    ​ ​ ​ ​ Silverland Assets Limited ​
    ​ ​ ​ ​ By: HSBC Trustee (Hong Kong) Limited, its sole member ​
    ​ ​ ​ ​
    By:
    /s/ Jamie Chi Wai SIU;
    /s/ Cherrie Kam Chi YEUNG
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Jamie Chi Wai SIU; Cherrie Kam Chi YEUNG​ ​
    ​ ​ ​ ​ Title: Authorised Signatories ​
    ​ ​ ​ ​ The Cai Family Trust ​
    ​ ​ ​ ​
    By: HSBC Trustee (Hong Kong) Limited, its trustee
    ​
    ​ ​ ​ ​
    By:
    /s/ Jamie Chi Wai SIU;
    /s/ Cherrie Kam Chi YEUNG
    ​
    ​
    ​
    ​ ​ ​ ​ Name: Jamie Chi Wai SIU; Cherrie Kam Chi YEUNG​ ​
    ​ ​ ​ ​ Title: Authorised Signatories ​
    ​ ​ ​ ​ Kui Cai ​
    ​ ​ ​ ​
    /s/ Kui Cai
    ​
    ​
     

    Get the next $NFH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NFH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NFH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Frontier Health Corporation Announces Completion of Going Private Transaction

    New Frontier Health Corporation ("NFH" or the "Company") (NYSE:NFH), operator of the premium healthcare services provider United Family Healthcare, today announced the completion of its merger (the "Merger") with Unicorn II Merger Sub Limited ("Merger Sub"), pursuant to the previously announced agreement and plan of merger, dated as of August 4, 2021 (the "Merger Agreement"), among the Company, Unicorn II Holdings Limited ("HoldCo"), Unicorn II Parent Limited ("Parent") and Merger Sub. As a result of the Merger, the Company became a wholly owned subsidiary of Parent and will cease to be a publicly traded company. Pursuant to the terms of the Merger Agreement, which was approved by the Comp

    1/26/22 4:05:00 PM ET
    $NFH
    Hospital/Nursing Management
    Health Care

    New Frontier Health Corporation Receives Notification from NYSE Regarding Delayed Filing of Semi-Annual Financial Information for the Half Year Ended June 30, 2021

    New Frontier Health Corporation (NYSE:NFH) ("NFH" or the "Company"), the operator of the premium healthcare services provider United Family Healthcare, today reported that, on January 4, 2022, the Company received a notice from the New York Stock Exchange (the "NYSE") Regulation stating that it is not in compliance with the NYSE's continued listing requirements under the timely filing criteria pursuant to Section 802.01E of the NYSE Listed Company Manual (the "Continued Listing Criteria") as a result of the Company's failure to timely file its semi-annual financial information for the half year ended June 30, 2021 on a Current Report on Form 6-K (the "1H 2021 6-K") with the SEC. The NYSE i

    1/11/22 4:10:00 PM ET
    $NFH
    Hospital/Nursing Management
    Health Care

    New Frontier Health Corporation Announces Shareholders' Approval of Merger Agreement and Warrantholders' Approval of Warrant Amendment

    New Frontier Health Corporation ("NFH" or the "Company") (NYSE:NFH), operator of the premium healthcare services provider United Family Healthcare, today announced that, at an extraordinary general meeting (the "EGM") held today, the Company's shareholders voted in favor of the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of August 4, 2021 (the "Merger Agreement"), among the Company, Unicorn II Holdings Limited ("HoldCo"), Unicorn II Parent Limited ("Parent") and Unicorn II Merger Sub Limited ("Merger Sub"), pursuant to which, Merger Sub will be merged with and into the Company with the Company continuing as the surviving company and beco

    1/7/22 6:00:00 AM ET
    $NFH
    Hospital/Nursing Management
    Health Care

    $NFH
    SEC Filings

    View All

    SEC Form 15-12B filed by New Frontier Health Corporation

    15-12B - New Frontier Health Corp (0001737422) (Filer)

    2/7/22 6:01:17 AM ET
    $NFH
    Hospital/Nursing Management
    Health Care

    SEC Form EFFECT filed by New Frontier Health Corporation

    EFFECT - New Frontier Health Corp (0001737422) (Filer)

    1/31/22 12:15:15 AM ET
    $NFH
    Hospital/Nursing Management
    Health Care

    SEC Form POS AM filed by New Frontier Health Corporation

    POS AM - New Frontier Health Corp (0001737422) (Filer)

    1/28/22 8:00:42 AM ET
    $NFH
    Hospital/Nursing Management
    Health Care

    $NFH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    New Frontier Health downgraded by Credit Suisse with a new price target

    Credit Suisse downgraded New Frontier Health from Outperform to Neutral and set a new price target of $12.00

    4/9/21 7:08:39 AM ET
    $NFH
    Hospital/Nursing Management
    Health Care

    $NFH
    Leadership Updates

    Live Leadership Updates

    View All

    New Frontier Health Corporation Announces Formation of Special Committee and Appointment of Advisors

    BEIJING--(BUSINESS WIRE)--New Frontier Health Corporation (“NFH” or the “Company”) (NYSE: NFH), operator of the premium healthcare services provider United Family Healthcare, today announced that its board of directors (the “Board”) has formed a special committee (the “Special Committee”) consisting of three independent directors, Dr. Edward Leong Che-hung, Professor Frederick Ma Si-hang and Mr. Lawrence Chia, to review and evaluate the previously announced preliminary non-binding “going private” proposal (the “Proposal”) set out in a letter dated February 9, 2021 from a buyer group consisting of New Frontier Public Holding Ltd. (“NFPH”), Carnival Investments Limited, a company affi

    3/18/21 8:00:00 AM ET
    $NFH
    Hospital/Nursing Management
    Health Care

    $NFH
    Financials

    Live finance-specific insights

    View All

    New Frontier Health Corporation Announces Fourth Quarter and Fiscal 2020 Financial Results

    BEIJING--(BUSINESS WIRE)--New Frontier Health Corporation (“NFH” or “the Company”) (NYSE: NFH), operator of the premium healthcare services provider United Family Healthcare ("UFH"), today announced its financial results for the fourth quarter and fiscal year ended December 31, 2020. Financial and Operating Highlights1 All comparisons made on both a year-over-year (“yoy”) and quarter-on-quarter (“qoq”) basis. 2 For the Quarter Ended December 31, 2020: Revenue increased by 2.2% yoy to RMB654.0 million from RMB639.7 million and increased by 4.4% from the prior quarter, as patient volume recovered from the COVID-19 pandemic onset. Net loss decreased to RMB101.4 million from RMB2

    4/8/21 6:00:00 AM ET
    $NFH
    Hospital/Nursing Management
    Health Care

    $NFH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by New Frontier Health Corporation (Amendment)

    SC 13D/A - New Frontier Health Corp (0001737422) (Subject)

    1/31/22 1:51:46 PM ET
    $NFH
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13D/A filed by New Frontier Health Corporation (Amendment)

    SC 13D/A - New Frontier Health Corp (0001737422) (Subject)

    1/27/22 6:58:30 AM ET
    $NFH
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13D/A filed by New Frontier Health Corporation (Amendment)

    SC 13D/A - New Frontier Health Corp (0001737422) (Subject)

    12/2/21 8:32:53 AM ET
    $NFH
    Hospital/Nursing Management
    Health Care